Definition
Fibrin-anti-polymerants are small synthetic peptides that can prevent the polymerisation of the thrombin-cleaved fibrinogen by interacting with fibrin monomers1.
Related peptides
These peptides bear a sequence similarity to the terminal sequence of the a- and ß-chains that are exposed following the removal of the fibrinopeptides A and B, respectively, by thrombin1.
Discovery
N-Terminal tetrapeptide analogs of fibrin alpha-chain were first synthesized and studied by Kawasaki et al., in 1992. The inhibitory effects of these peptides on fibrinogen/thrombin clotting were examined. They found that, of the synthetic peptides, amide analogs of Gly-Pro-Arg-Pro exhibited a more potent inhibitory effect2. Later the same group found that, the extension of peptide chain from N-terminal tripeptide decreased the inhibitory effect. The most potent effect was shown by a new N-terminal decapeptide analog, H-Gly-Pro-Arg-Pro-Pro-Glu-Arg-His-Gln-Ser-NH23.
Structural Characteristics
Some commercially available synthetic fibrin anti polymerants bear the following
sequences:
H-Gly-His-Arg-Pro-OH
H-Gly-Pro-Arg-OH
H-Gly-Pro-Arg-Pro-OH
H-Gly-Pro-Arg-Pro-NH2
H-Gly-Pro-Arg-Pro-Pro-Glu-Arg-His-Gln-Ser-NH2
The peptide H-Gly-Pro-Arg-Pro-OH has a sequence similar to the terminal sequence of the a-chain that is exposed following the removal of the fibrinopeptide A by thrombin.The peptide H-Gly-His-Arg-Pro-OH is similar to the terminal sequence of the ß chain after removal of fibrinopeptide B by thrombin. The extension of peptide chain from N-terminal tripeptide decreased the inhibitory effect3.
Mode of Action
The peptide H-Gly-Pro-Arg-Pro-OH can prevent the polymerisation of the thrombin-cleaved fibrinogen by competitively blocking the interaction between the fibrin monomers1.
Functions
Fibrin anti-polymerants are mainly used in various structure-function studies of enzymes and structural proteins like fibrinogen, fibrin etc1.
References
1.Dowd AJ, McGonigle S, Dalton JP (1995). Fasciola hepatica cathepsin L proteinase cleaves fibrinogen and produces a novel type of fibrin clot. Eur. J. Biochem, 232: 241-246.
2.Kawasaki K, Hirase K, Miyano M, Tsuji T, Iwamoto M (1992). Amino acids and peptides. XVI. Synthesis of N-terminal tetrapeptide analogs of fibrin alpha-chain and their inhibitory effects on fibrinogen/thrombin clotting. Chem Pharm Bull (Tokyo). 40(12):3253-3260.
3.Kawasaki K, Tsuji T, Hirase K, Miyano M, Inouye S, Iwamoto M (1993). Amino acids and peptides. XVII. Synthesis of peptides related to N-terminal portion of fibrin alpha-chain and their inhibitory effect on fibrinogen/thrombin clotting. Chem Pharm Bull (Tokyo). 41(3):525-528.
Tuesday, August 25, 2009
Angiogenin and Fragments
Definition
Angiogenin (ANG), a 14,124 Da protein that has been implicated in angiogenesis in tumor progression. It is secreted by tumor cells, a potent inducer of neovascularization1.
Discovery
In 1885, Fett et al., first isolated and characterized angiogenin from medium conditioned by HT-29 human colon adenocarcinoma cells1 and later from normal mammalian plasma2 and milk. It has been subsequently isolated from human, bovine, rabbit, pig & mouse sera and bovine milk. Angiogenin has ribonucleolytic activity with 33% sequence homology to pancreatic RNAse A3. A synthetic peptide ’H-Glu-Asn-Gly-Leu-Pro-Val-His-Leu-Asp-Gln-Ser-Ile-Phe-Arg-Arg-OH (108-122) corresponding to the C-terminal region of ANG inhibits the enzymatic and biological activities of angiogenin4. Several C-terminal synthetic peptides, including (Ang 108-123), significantly decreases angiogenin-induced neovascularization.
Structural characteristics
Acharya et al., determined the crystal structure of human antigenic at 2.4 0A. Overall Structure features a kidney shaped tertiary fold reminiscent of RNase A. The ribonucleolytic active center (His-13, His-114, and Lys-40) and the putative receptor binding site, both of which are critically involved in biological functions are distinct from Rnase A5. The central core of the molecule consists of P structure with a pair of antiparallel twisted forming the main topology with residues Ser-72 and Gly-99 at the apices. Two additional strands on either side of these central strands (residues 41-47; 111-116) complete the major sheet structure. There are 3 helices H1, residues 3-14, H2, residues 22-33 and H3, residues 49-58 present in the structure.
Mechanism of action
Four aspects of ANG have been discovered that is necessary for the process of ANG-induced angiogenesis,ANG exerts its ribonucleolytic activity-ANG has a very weak 105-106 lower ribonucleolytic activity than that of RNase A. This is because the pyrimidine binding site of ANG is “obstructed” by the glutamine (Gln)117 residue. However, ribonucleolytic activity of ANG is crucial for angiogenesis.ANG stimulates basement membrane degradation-ANG binds to a-actin on endothelial cell surface; ANG-actin complexes dissociate from the cell surface and accelerate tissue type plasminogen activator (tPA)-catalyzed generation of plasmin from plasminogen. ANG-actin complexes promote the degradation of basement membrane and extracellular matrix. This complex allows endothelial cells to penetrate and migrate into the perivascular tissue. Basement membrane degradation is an essential feature of angiogenesis. ANG activates signaling transduction- ANG binds to a 170-kDa receptor located on the endothelial cell surface and elicits second messenger systems. Binding of ANG to cell surface actin results in activation of a cell-associated protease system that promotes cell invasion. ERK1/2, protein kinase B/Akt1 pathways have been proposed to be activated by ANG stimulation. ANG nuclear translocation-Angiogenin undergoes nuclear translocation in endothelial cells via receptor-mediated endocytosis and nuclear localization sequence-assisted nuclear import. A nuclear localization signal (NLS), lies in 31-RRRGL-35 of the protein. Upon nuclear translocation it enhances rRNA transcription.
Functions
Functions of ANG in Angiogenesis-As a key angiogenic factor, ANG interacts with endothelial and smooth muscle cells to induce a wide range of cellular responses including cell migration, invasion, proliferation, and formation of tubular structures. ANG has also been reported to induce the proliferation of cancer cells directly. Recently, ANG gene was identified to be a potential amyotrophic lateral sclerosis (ALS) related gene6. ANG induces tumor growth in various types of human cancers, including breast, cervical, colon, colorectal, endometrial, gastric, liver, kidney, ovarian, pancreatic, prostate, and urothelial cancers, as well as astrocytoma, leukemia, lymphoma, melanoma, osteosarcoma, and Wilms’ tumor 6. ANG may be related with amyotrophic lateral sclerosis- Amyotrophic lateral sclerosis (ALS) is a progressive late onset neurodegenerative disorder affecting upper and lower motoneurons (MNs). Vascular endothelial growth factor was the first angiogenic factor shown to contribute to the pathogenesis of ALS 7.
References
1. Fett JW, Strydom DJ, Lobb RR, Alderman EM, Bethune JL, Riordan JF, Vallee BL (1985). Isolation and characterization of angiogenin, an antigenic protein from human carcinoma cells. Biochemistry, 24: 5480-5486.
2. Shapiro R, Strydom DJ, Olson KA, Vallee BL (1987). Isolation of angiogenin from normal human plasma. Biochemistry, 26: 5141-5146.
3. Strydom DJ, Fett JW, Lobb RR, Alderman EM, Bethune JL, Riordan JF, Vallee BL (1985). Amino acid sequence of human tumor derived angiogenin. Biochemistry, 24(20): 5486–5494.
4. Rybak SM, Auld DS, St Clair DK, Yao QZ, Fett JW (1989). C-terminal angiogenin peptides inhibit the biological and enzymatic activities of angiogenin. Biochem. Biophys. Res. Commun, 162: 535–543.
5. Acharya KR, Shapiro R, Allen SC, Riordan JF, Vallee BL (1994). Crystal structure of human angiogenin reveals the structural basis for its functional divergence from ribonuclease. Proc Natl Acad Sci USA, 91: 2915-2919.
6. Yoshioka N, Wang L, Kishimoto K, Tsuji T, Hu GF (2006). A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation. Proc Natl Acad Sci USA, 103: 14519-14524.
7. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, Van Dorpe J, Hellings P, Gorselink M, Heymans S, Theilmeier G, Dewerchin M, Laudenbach V, Vermylen P, Raat H, Acker T, Vleminckx V, Van Den Bosch L, Cashman N, Fujisawa H, Drost MR, Sciot R, Bruyninckx F, Hicklin DJ, Ince C, Gressens P, Lupu F, Plate KH, Robberecht W, Herbert JM, Collen D, Carmeliet P(2001). Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Gene, 28:131-138.
Angiogenin (ANG), a 14,124 Da protein that has been implicated in angiogenesis in tumor progression. It is secreted by tumor cells, a potent inducer of neovascularization1.
Discovery
In 1885, Fett et al., first isolated and characterized angiogenin from medium conditioned by HT-29 human colon adenocarcinoma cells1 and later from normal mammalian plasma2 and milk. It has been subsequently isolated from human, bovine, rabbit, pig & mouse sera and bovine milk. Angiogenin has ribonucleolytic activity with 33% sequence homology to pancreatic RNAse A3. A synthetic peptide ’H-Glu-Asn-Gly-Leu-Pro-Val-His-Leu-Asp-Gln-Ser-Ile-Phe-Arg-Arg-OH (108-122) corresponding to the C-terminal region of ANG inhibits the enzymatic and biological activities of angiogenin4. Several C-terminal synthetic peptides, including (Ang 108-123), significantly decreases angiogenin-induced neovascularization.
Structural characteristics
Acharya et al., determined the crystal structure of human antigenic at 2.4 0A. Overall Structure features a kidney shaped tertiary fold reminiscent of RNase A. The ribonucleolytic active center (His-13, His-114, and Lys-40) and the putative receptor binding site, both of which are critically involved in biological functions are distinct from Rnase A5. The central core of the molecule consists of P structure with a pair of antiparallel twisted forming the main topology with residues Ser-72 and Gly-99 at the apices. Two additional strands on either side of these central strands (residues 41-47; 111-116) complete the major sheet structure. There are 3 helices H1, residues 3-14, H2, residues 22-33 and H3, residues 49-58 present in the structure.
Mechanism of action
Four aspects of ANG have been discovered that is necessary for the process of ANG-induced angiogenesis,ANG exerts its ribonucleolytic activity-ANG has a very weak 105-106 lower ribonucleolytic activity than that of RNase A. This is because the pyrimidine binding site of ANG is “obstructed” by the glutamine (Gln)117 residue. However, ribonucleolytic activity of ANG is crucial for angiogenesis.ANG stimulates basement membrane degradation-ANG binds to a-actin on endothelial cell surface; ANG-actin complexes dissociate from the cell surface and accelerate tissue type plasminogen activator (tPA)-catalyzed generation of plasmin from plasminogen. ANG-actin complexes promote the degradation of basement membrane and extracellular matrix. This complex allows endothelial cells to penetrate and migrate into the perivascular tissue. Basement membrane degradation is an essential feature of angiogenesis. ANG activates signaling transduction- ANG binds to a 170-kDa receptor located on the endothelial cell surface and elicits second messenger systems. Binding of ANG to cell surface actin results in activation of a cell-associated protease system that promotes cell invasion. ERK1/2, protein kinase B/Akt1 pathways have been proposed to be activated by ANG stimulation. ANG nuclear translocation-Angiogenin undergoes nuclear translocation in endothelial cells via receptor-mediated endocytosis and nuclear localization sequence-assisted nuclear import. A nuclear localization signal (NLS), lies in 31-RRRGL-35 of the protein. Upon nuclear translocation it enhances rRNA transcription.
Functions
Functions of ANG in Angiogenesis-As a key angiogenic factor, ANG interacts with endothelial and smooth muscle cells to induce a wide range of cellular responses including cell migration, invasion, proliferation, and formation of tubular structures. ANG has also been reported to induce the proliferation of cancer cells directly. Recently, ANG gene was identified to be a potential amyotrophic lateral sclerosis (ALS) related gene6. ANG induces tumor growth in various types of human cancers, including breast, cervical, colon, colorectal, endometrial, gastric, liver, kidney, ovarian, pancreatic, prostate, and urothelial cancers, as well as astrocytoma, leukemia, lymphoma, melanoma, osteosarcoma, and Wilms’ tumor 6. ANG may be related with amyotrophic lateral sclerosis- Amyotrophic lateral sclerosis (ALS) is a progressive late onset neurodegenerative disorder affecting upper and lower motoneurons (MNs). Vascular endothelial growth factor was the first angiogenic factor shown to contribute to the pathogenesis of ALS 7.
References
1. Fett JW, Strydom DJ, Lobb RR, Alderman EM, Bethune JL, Riordan JF, Vallee BL (1985). Isolation and characterization of angiogenin, an antigenic protein from human carcinoma cells. Biochemistry, 24: 5480-5486.
2. Shapiro R, Strydom DJ, Olson KA, Vallee BL (1987). Isolation of angiogenin from normal human plasma. Biochemistry, 26: 5141-5146.
3. Strydom DJ, Fett JW, Lobb RR, Alderman EM, Bethune JL, Riordan JF, Vallee BL (1985). Amino acid sequence of human tumor derived angiogenin. Biochemistry, 24(20): 5486–5494.
4. Rybak SM, Auld DS, St Clair DK, Yao QZ, Fett JW (1989). C-terminal angiogenin peptides inhibit the biological and enzymatic activities of angiogenin. Biochem. Biophys. Res. Commun, 162: 535–543.
5. Acharya KR, Shapiro R, Allen SC, Riordan JF, Vallee BL (1994). Crystal structure of human angiogenin reveals the structural basis for its functional divergence from ribonuclease. Proc Natl Acad Sci USA, 91: 2915-2919.
6. Yoshioka N, Wang L, Kishimoto K, Tsuji T, Hu GF (2006). A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation. Proc Natl Acad Sci USA, 103: 14519-14524.
7. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, Van Dorpe J, Hellings P, Gorselink M, Heymans S, Theilmeier G, Dewerchin M, Laudenbach V, Vermylen P, Raat H, Acker T, Vleminckx V, Van Den Bosch L, Cashman N, Fujisawa H, Drost MR, Sciot R, Bruyninckx F, Hicklin DJ, Ince C, Gressens P, Lupu F, Plate KH, Robberecht W, Herbert JM, Collen D, Carmeliet P(2001). Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Gene, 28:131-138.
Tuesday, August 18, 2009
Intermedins
Definition
Intermedin (IMD) is a novel member of the calcitonin gene-related peptide (CGRP) family which also includes adrenomedullin (AM).
Discovery
In early 2004, a novel peptide was independently identified by two separate groups. Roh and colleagues initially identified human IMD from an expressed sequence tag and used phylogenetic profiling to identify the peptide in other mammals and nonvertebrates. Immunohistochemical analysis of peptide expression revealed that high levels of the peptide and/or preprohormone were present in cells within the intermediate lobe of the pituitary; hence, the group called the peptide intermedin1. At the same time, Takei et al. were examining a rat cDNA library for potential mammalian homologs of the five identified puffer fish adrenomedullin (AM) family members. They identified a 148-amino acid preprohormone that was processed into a 47-amino acid, mature peptide with 33% sequence homology to AM and 71% homology to puffer fish AM2 and thus referred to the peptide as mammalian AM22.
Structural Characteristics
The human IMD gene is believed to encode a prepropeptide of 148 amino acids with a signal peptide for secretion at the N terminus, which may generate a 47-amino acid mature peptide (IMD1–47) i.e. IMDL and a shorter 40-amino acid one (IMD8–47) i.e. IMDS by proteolytic cleavage at the N-terminal proximate basic residues followed by an amidated C terminus. Intermedins has a stretch of 47 residues at the C terminus is flanked by dibasic proteolytic cleavage sites at the N terminus and an a-amidation donor residue at the C terminus. The putative mature region of intermedin shares 28% sequence identity with ADM and 20% with CGRP. Importantly, Intermedins adopts an N-terminal disulfide- bonded loop leading into an a-helix, followed by a disordered structure that is shared by all calcitonin/CGRP family peptides. Analysis of orthologous intermedins indicate that the positions of N-terminal dibasic cleavage sites vary by a few amino acids among different species, whereas an arginine residue seven amino acids downstream of the dibasic cleavage motif of human intermedin is conserved in all species, suggesting that the mature intermedin from human and other species could be a 40-amino acid peptide3.
Mode of action
Intermedin activates the cAMP-dependent Pathway via the CGRP Receptor— A study shows that treatment of human neuroblastoma SK-N-MC cells and rat L6 skeletal myoblast cells, known to express different levels of calcitonin receptor-like receptor (CRLR) and receptor activity-modifying protein (RAMPs), with synthetic intermedin peptides resulted in increased cAMP production, whereas treatment with the truncated amidated intermedin fragment (intermedin (IMD)- (17–47)), or a 31-amino acid peptide from the preproregion of human intermedin (prointermedin-(55–85)) had no effect in either cell line. This implied that a-amidation and residues 8–16 of intermedin are important for intermedin bioactivity. Further it was also shown that the stimulatory effect of intermedin was suppressed by cotreatment with a calcitonin gene-related peptide (CGRP) receptor antagonist (CGRP-(8–37)) in L6 cells3.
Functions
Intermedin/Adrenomedullin-2 elevate blood pressure and inhibit food and water intake - Intermedin is homologous to adrenomedullin (AM) and can activate both the AM and calcitonin gene-related peptide (CGRP) receptors. It has been reported that administration of IMD into the lateral cerebroventricle (i.c.v.) of rats caused significant, long-lasting elevations in mean arterial pressure and heart rate. These elevations are similar to the effects of CGRP and significantly greater than the effects of AM. IMD-induced elevations in mean arterial pressure were inhibited by i.c.v. administration of phentolamine indicating that IMD activates the sympathetic nervous system. I.c.v administration of IMD also inhibited food and water intake. The effects on feeding are likely related to activation of the CGRP receptor and are independent of the effects on water intake, which are likely through the AM receptor. A study indicate that IMD has potent actions within the CNS that may be a result of the combined activation of both the AM and CGRP receptors4.
Expression of the Counter-Regulatory Peptide Intermedin is Augmented in the Presence of Oxidative Stress in Hypertrophied Cardiomyocytes - A study was done using the spontaneously hypertensive rat (SHR) and normotensive Wistar Kyoto (WKY), to examine the presence of myocardial oxidative stress, concentric hypertrophy expression of IMD, AM and receptor components. It was found that in left and right ventricularm cardiomyocytes from SHR vs. WKY cell width (26% left, 15% right) and mRNA expression of hypertrophic markers ANP (2.7 fold left, 2.7 fold right) and BNP (2.2 fold left, 2.0 fold right) were enhanced. In left ventricular cardiomyocytes only oxidative stress was indicated by increased membrane protein carbonyl content (71%) and augmented production of O2- anion (64%) and IMD (6.8 fold), RAMP1 (2.5 fold) and RAMP3 (2.0 fold) mRNA was increased while AM and RAMP2 mRNA was not altered and abundance of RAMP1 (by 48%), RAMP2 (by 41%) and RAMP3 (by 90%) monomers in cell membranes was decreased. This implied that robust augmentation of IMD expression in hypertrophied left ventricular cardiomyocytes indicates a prominent role for this counter regulatory peptide in the adaptation of the SHR myocardium to the stresses imposed by chronic hypertension5.
References
1. Roh J, Chang CL, Bhalla A, Klein C, and Hsu SYT (2004). Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complex. J. Biol. Chem., 279, 7264–7274.
2. Takei Y, Inoue K, Ogoshi M, Kawahara T, Bannai H, and Miyano S (2004). Novel fish-derived adrenomedullin in mammals: structure and possible function. Peptides, 25, 1643- 1656.
3.Jaesook Roh, Chia Lin Chang, Alka Bhalla, Cynthia Klein, and Sheau Yu Teddy Hsu (2004). Intermedin Is a Calcitonin/Calcitonin Gene-related Peptide Family Peptide Acting through the Calcitonin Receptor-liken Receptor/Receptor Activity-modifying Protein Receptor Complexes. J. Bio. Chem., 279 (20), 7264–7274.
4.Taylor MM, Bagley SL, Samson WK (2004). Intermedin/Adrenomedullin-2 acts within the central nervous system to elevate blood pressure and inhibit food and water intake. Am. J Physiol. Regul. Integr. Comp. Physiol., 288, R919-R927.
5.David Bell, Y Zhao, Francis PG. McCoy, Adrian Devine and Barbara J. McDermott (2008). Expression of the Counter-Regulatory Peptide Intermedin is augmented in the Presence of Oxidative Stress in Hypertrophied Cardiomyocytes. Cell. Physiol. Biochem., 21, 409-420.
Intermedin (IMD) is a novel member of the calcitonin gene-related peptide (CGRP) family which also includes adrenomedullin (AM).
Discovery
In early 2004, a novel peptide was independently identified by two separate groups. Roh and colleagues initially identified human IMD from an expressed sequence tag and used phylogenetic profiling to identify the peptide in other mammals and nonvertebrates. Immunohistochemical analysis of peptide expression revealed that high levels of the peptide and/or preprohormone were present in cells within the intermediate lobe of the pituitary; hence, the group called the peptide intermedin1. At the same time, Takei et al. were examining a rat cDNA library for potential mammalian homologs of the five identified puffer fish adrenomedullin (AM) family members. They identified a 148-amino acid preprohormone that was processed into a 47-amino acid, mature peptide with 33% sequence homology to AM and 71% homology to puffer fish AM2 and thus referred to the peptide as mammalian AM22.
Structural Characteristics
The human IMD gene is believed to encode a prepropeptide of 148 amino acids with a signal peptide for secretion at the N terminus, which may generate a 47-amino acid mature peptide (IMD1–47) i.e. IMDL and a shorter 40-amino acid one (IMD8–47) i.e. IMDS by proteolytic cleavage at the N-terminal proximate basic residues followed by an amidated C terminus. Intermedins has a stretch of 47 residues at the C terminus is flanked by dibasic proteolytic cleavage sites at the N terminus and an a-amidation donor residue at the C terminus. The putative mature region of intermedin shares 28% sequence identity with ADM and 20% with CGRP. Importantly, Intermedins adopts an N-terminal disulfide- bonded loop leading into an a-helix, followed by a disordered structure that is shared by all calcitonin/CGRP family peptides. Analysis of orthologous intermedins indicate that the positions of N-terminal dibasic cleavage sites vary by a few amino acids among different species, whereas an arginine residue seven amino acids downstream of the dibasic cleavage motif of human intermedin is conserved in all species, suggesting that the mature intermedin from human and other species could be a 40-amino acid peptide3.
Mode of action
Intermedin activates the cAMP-dependent Pathway via the CGRP Receptor— A study shows that treatment of human neuroblastoma SK-N-MC cells and rat L6 skeletal myoblast cells, known to express different levels of calcitonin receptor-like receptor (CRLR) and receptor activity-modifying protein (RAMPs), with synthetic intermedin peptides resulted in increased cAMP production, whereas treatment with the truncated amidated intermedin fragment (intermedin (IMD)- (17–47)), or a 31-amino acid peptide from the preproregion of human intermedin (prointermedin-(55–85)) had no effect in either cell line. This implied that a-amidation and residues 8–16 of intermedin are important for intermedin bioactivity. Further it was also shown that the stimulatory effect of intermedin was suppressed by cotreatment with a calcitonin gene-related peptide (CGRP) receptor antagonist (CGRP-(8–37)) in L6 cells3.
Functions
Intermedin/Adrenomedullin-2 elevate blood pressure and inhibit food and water intake - Intermedin is homologous to adrenomedullin (AM) and can activate both the AM and calcitonin gene-related peptide (CGRP) receptors. It has been reported that administration of IMD into the lateral cerebroventricle (i.c.v.) of rats caused significant, long-lasting elevations in mean arterial pressure and heart rate. These elevations are similar to the effects of CGRP and significantly greater than the effects of AM. IMD-induced elevations in mean arterial pressure were inhibited by i.c.v. administration of phentolamine indicating that IMD activates the sympathetic nervous system. I.c.v administration of IMD also inhibited food and water intake. The effects on feeding are likely related to activation of the CGRP receptor and are independent of the effects on water intake, which are likely through the AM receptor. A study indicate that IMD has potent actions within the CNS that may be a result of the combined activation of both the AM and CGRP receptors4.
Expression of the Counter-Regulatory Peptide Intermedin is Augmented in the Presence of Oxidative Stress in Hypertrophied Cardiomyocytes - A study was done using the spontaneously hypertensive rat (SHR) and normotensive Wistar Kyoto (WKY), to examine the presence of myocardial oxidative stress, concentric hypertrophy expression of IMD, AM and receptor components. It was found that in left and right ventricularm cardiomyocytes from SHR vs. WKY cell width (26% left, 15% right) and mRNA expression of hypertrophic markers ANP (2.7 fold left, 2.7 fold right) and BNP (2.2 fold left, 2.0 fold right) were enhanced. In left ventricular cardiomyocytes only oxidative stress was indicated by increased membrane protein carbonyl content (71%) and augmented production of O2- anion (64%) and IMD (6.8 fold), RAMP1 (2.5 fold) and RAMP3 (2.0 fold) mRNA was increased while AM and RAMP2 mRNA was not altered and abundance of RAMP1 (by 48%), RAMP2 (by 41%) and RAMP3 (by 90%) monomers in cell membranes was decreased. This implied that robust augmentation of IMD expression in hypertrophied left ventricular cardiomyocytes indicates a prominent role for this counter regulatory peptide in the adaptation of the SHR myocardium to the stresses imposed by chronic hypertension5.
References
1. Roh J, Chang CL, Bhalla A, Klein C, and Hsu SYT (2004). Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complex. J. Biol. Chem., 279, 7264–7274.
2. Takei Y, Inoue K, Ogoshi M, Kawahara T, Bannai H, and Miyano S (2004). Novel fish-derived adrenomedullin in mammals: structure and possible function. Peptides, 25, 1643- 1656.
3.Jaesook Roh, Chia Lin Chang, Alka Bhalla, Cynthia Klein, and Sheau Yu Teddy Hsu (2004). Intermedin Is a Calcitonin/Calcitonin Gene-related Peptide Family Peptide Acting through the Calcitonin Receptor-liken Receptor/Receptor Activity-modifying Protein Receptor Complexes. J. Bio. Chem., 279 (20), 7264–7274.
4.Taylor MM, Bagley SL, Samson WK (2004). Intermedin/Adrenomedullin-2 acts within the central nervous system to elevate blood pressure and inhibit food and water intake. Am. J Physiol. Regul. Integr. Comp. Physiol., 288, R919-R927.
5.David Bell, Y Zhao, Francis PG. McCoy, Adrian Devine and Barbara J. McDermott (2008). Expression of the Counter-Regulatory Peptide Intermedin is augmented in the Presence of Oxidative Stress in Hypertrophied Cardiomyocytes. Cell. Physiol. Biochem., 21, 409-420.
Insulin Receptor Tyrosine Kinase
Definiion
The insulin receptor is a transmembrane receptor that is activated by insulin. It belongs to the large class of tyrosine kinase receptors.
Structural Characteristics
The insulin receptor is composed of two a-subunits that are each linked to a b-subunit and to each other by disulfide bonds. Both subunits are derived from a single proreceptor by proteolytic processing at a cleavage site consisting of four basic amino acids. The mature heterotetramer (a2b2) contains complex N-linked carbohydrate side chains capped by terminal sialic acid residues and migrates with a molecular mass of 300400 kDa. The a-subunits are located entirely outside of the cell and contain the insulin binding site(s), whereas the intracellular portion of the b subunit contains the insulin-regulated tyrosine protein kinase. The insulin receptor family contains two other structurally related molecules, the insulin-like growth factor (IGF-1) receptor and the insulin receptor – related receptor, an orphan receptor. This family shares more than 80% amino acid sequence identity in the kinase domain but has low amino acid sequence identity in the extracellular domain1.
Mode of Action
The physiological effects of insulin are mediated by its cell surface receptor, a a2b2 transmembrane glycoprotein with intrinsic protein tyrosine activity. Binding of insulin to the extracellular a-chains results in autophosphorylation of specific tyrosine residues in the portion of the b-chains: two in the juxtamembrane region, three in the kinase (catalytic) domain, and two in the C-terminal tail2. Autophosphorylation of Tyr1158, Tyr1162 and Tyr1163 in the activation loop (A-loop) of the kinase domain is critical for stimulation of kinase activity and function.
The activation loop (A-loop) of the kinase undergoes a major conformational change upon autophosphorylation of Tyr1158, Tyr1162 and Tyr1163 within the loop, resulting in unrestricted access of ATP and protein substrates to the kinase active site3.
An important consequence of activation is the recruitment of insulin receptor substrate-1 (IRS-1) and other effector molecules such as phosphatidylinositol 3'-kinase (PI-3K), Ras GTP activating protein (Ras GAP) and phospholipase C-y (PLCyj and adaptor molecules, including Shc and Grb2 [1]. Each of these effectors and adaptors contain Src homology 2 (SH2) domains that bind phosphotyrosines with high affinity. Importantly, it is IRS-1 that is the main target for these SH2-containing proteins rather than the insulin receptor itself. Eventually these transient complexes formed with IRS-1 activate a number of pathways involving serine/threonine kinases, such as the mitogenactivated- protein (MAP) kinase which ultimately lead to the initiation of protein synthesis and to the translocation of an insulin-sensitive glucose transporter to the cell surface4.
Functions
Effects of hypercortisolemia and insulin receptor function - Activation of skeletal muscle insulin receptor tyrosine kinase in vitro and in vivo was studied in two rat models of insulin resistance: insulinopenic diabetes and hypercortisolemia. In control rats, intravenous insulin administration resulted in dose-dependent in vivo activation of the muscle insulin receptor kinase towards histone H2b. Half-maximal and maximal activation were observed 5 min after injecting 0.1 and 0.5 U insulin/100 g, respectively. Diabetes (7 days) induced with streptozotocin did not affect insulin binding affinity of solubilized muscle receptors but depressed receptor kinase activation in vivo by 52 or 40% after intravenous insulin administration. Cortisone treatment (5 days) resulting in weight loss, hyperglycemia, and hyperinsulinemia did not affect the number, insulin binding affinity, or kinase activity of solubilized receptors activated with insulin in vitro or in vivo5.
Insulin Internalization in the Absence of the Insulin Receptor Tyrosine Kinase Domain Is Insufficient for Mediating Intracellular Biological Effects - The intracellular portion of the human insulin receptor (hIR) ß-subunit contains distinct functional domains including the exon 16-encoded juxtamembrane (JM) domain that mediates endocytosis, and the tyrosine kinase (TK) domain that mediates insulin's metabolic and mitogenic actions. To explore the functional relationship between these domains and to determine the role of insulin internalization in insulin action, a study was conducted using hIR mutant, truncated at Glu-1012. This truncation removes the carboxyl-terminal 343 amino acids containing essentially all of the TK domain but leaves behind the exon 16-encoded JM domain that is necessary for endocytosis, plus an additional 35 amino acids downstream. It was found that the wild-type (hIR-WT) and mutant (hIR?343) receptors were stably expressed in CHO cells. In cells expressing hIR-WT, insulin markedly enhanced tyrosine phosphorylation of the ß-subunit and of the endogenous 185 kDa substrate whereas these effects were completely absent in cells expressing hIR?343. The hIR?343 receptors retained the ability to internalize a significant amount of surface-bound insulin at 37°C. However, they were unable to mediate either short or long-term biological effects such as insulin-stimulated glucose uptake and DNA synthesis. Further results indicate that the hIR ß-subunit JM and TK domains can be functionally uncoupled, and that insulin internalization in the absence of hIR TK domain and kinase activity is insufficient for mediating intracellular insulin action6.
References
1.NQ McDonald, J Murray – Rust and TL Blundell (1995).The first structure of a receptor tyrosine kinase domain: a further step in understanding the molecular basis of insulin action. Structure, 3, 1-6.
2.Feener EP, Backer JM., King GL, Wilden PA, Sun XJ, Kahn CR and White MF (1993). Insulin stimulates serine and tyrosine phosphorylation in the juxtamembrane region of the insulin receptor. J. Biol. Chem., 268, 11256–11264.
3.Stevan R Hubbard (1997). Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. The EMBO Journal., 16(18), 5573–5581.
4.White MF & Kahn CR (1994). The insulin signalling system . J. Biol. Chem., 269, 1-4.
5.NE Block and MG Buse (1989). Effects of hypercortisolemia and diabetes on skeletal muscle insulin receptor function in vitro and in vivo. Am. J. Physiol. Endocrino.l Metab., 256, E39-E48.
6.Dorota B. Schranz, Arif MK Rohilla, Celia Anderson, William M Wood and Paulos Berhanu (1996). Insulin Internalization in the Absence of the Insulin Receptor Tyrosine Kinase Domain Is Insufficient for Mediating Intracellular Biological Effects.
The insulin receptor is a transmembrane receptor that is activated by insulin. It belongs to the large class of tyrosine kinase receptors.
Structural Characteristics
The insulin receptor is composed of two a-subunits that are each linked to a b-subunit and to each other by disulfide bonds. Both subunits are derived from a single proreceptor by proteolytic processing at a cleavage site consisting of four basic amino acids. The mature heterotetramer (a2b2) contains complex N-linked carbohydrate side chains capped by terminal sialic acid residues and migrates with a molecular mass of 300400 kDa. The a-subunits are located entirely outside of the cell and contain the insulin binding site(s), whereas the intracellular portion of the b subunit contains the insulin-regulated tyrosine protein kinase. The insulin receptor family contains two other structurally related molecules, the insulin-like growth factor (IGF-1) receptor and the insulin receptor – related receptor, an orphan receptor. This family shares more than 80% amino acid sequence identity in the kinase domain but has low amino acid sequence identity in the extracellular domain1.
Mode of Action
The physiological effects of insulin are mediated by its cell surface receptor, a a2b2 transmembrane glycoprotein with intrinsic protein tyrosine activity. Binding of insulin to the extracellular a-chains results in autophosphorylation of specific tyrosine residues in the portion of the b-chains: two in the juxtamembrane region, three in the kinase (catalytic) domain, and two in the C-terminal tail2. Autophosphorylation of Tyr1158, Tyr1162 and Tyr1163 in the activation loop (A-loop) of the kinase domain is critical for stimulation of kinase activity and function.
The activation loop (A-loop) of the kinase undergoes a major conformational change upon autophosphorylation of Tyr1158, Tyr1162 and Tyr1163 within the loop, resulting in unrestricted access of ATP and protein substrates to the kinase active site3.
An important consequence of activation is the recruitment of insulin receptor substrate-1 (IRS-1) and other effector molecules such as phosphatidylinositol 3'-kinase (PI-3K), Ras GTP activating protein (Ras GAP) and phospholipase C-y (PLCyj and adaptor molecules, including Shc and Grb2 [1]. Each of these effectors and adaptors contain Src homology 2 (SH2) domains that bind phosphotyrosines with high affinity. Importantly, it is IRS-1 that is the main target for these SH2-containing proteins rather than the insulin receptor itself. Eventually these transient complexes formed with IRS-1 activate a number of pathways involving serine/threonine kinases, such as the mitogenactivated- protein (MAP) kinase which ultimately lead to the initiation of protein synthesis and to the translocation of an insulin-sensitive glucose transporter to the cell surface4.
Functions
Effects of hypercortisolemia and insulin receptor function - Activation of skeletal muscle insulin receptor tyrosine kinase in vitro and in vivo was studied in two rat models of insulin resistance: insulinopenic diabetes and hypercortisolemia. In control rats, intravenous insulin administration resulted in dose-dependent in vivo activation of the muscle insulin receptor kinase towards histone H2b. Half-maximal and maximal activation were observed 5 min after injecting 0.1 and 0.5 U insulin/100 g, respectively. Diabetes (7 days) induced with streptozotocin did not affect insulin binding affinity of solubilized muscle receptors but depressed receptor kinase activation in vivo by 52 or 40% after intravenous insulin administration. Cortisone treatment (5 days) resulting in weight loss, hyperglycemia, and hyperinsulinemia did not affect the number, insulin binding affinity, or kinase activity of solubilized receptors activated with insulin in vitro or in vivo5.
Insulin Internalization in the Absence of the Insulin Receptor Tyrosine Kinase Domain Is Insufficient for Mediating Intracellular Biological Effects - The intracellular portion of the human insulin receptor (hIR) ß-subunit contains distinct functional domains including the exon 16-encoded juxtamembrane (JM) domain that mediates endocytosis, and the tyrosine kinase (TK) domain that mediates insulin's metabolic and mitogenic actions. To explore the functional relationship between these domains and to determine the role of insulin internalization in insulin action, a study was conducted using hIR mutant, truncated at Glu-1012. This truncation removes the carboxyl-terminal 343 amino acids containing essentially all of the TK domain but leaves behind the exon 16-encoded JM domain that is necessary for endocytosis, plus an additional 35 amino acids downstream. It was found that the wild-type (hIR-WT) and mutant (hIR?343) receptors were stably expressed in CHO cells. In cells expressing hIR-WT, insulin markedly enhanced tyrosine phosphorylation of the ß-subunit and of the endogenous 185 kDa substrate whereas these effects were completely absent in cells expressing hIR?343. The hIR?343 receptors retained the ability to internalize a significant amount of surface-bound insulin at 37°C. However, they were unable to mediate either short or long-term biological effects such as insulin-stimulated glucose uptake and DNA synthesis. Further results indicate that the hIR ß-subunit JM and TK domains can be functionally uncoupled, and that insulin internalization in the absence of hIR TK domain and kinase activity is insufficient for mediating intracellular insulin action6.
References
1.NQ McDonald, J Murray – Rust and TL Blundell (1995).The first structure of a receptor tyrosine kinase domain: a further step in understanding the molecular basis of insulin action. Structure, 3, 1-6.
2.Feener EP, Backer JM., King GL, Wilden PA, Sun XJ, Kahn CR and White MF (1993). Insulin stimulates serine and tyrosine phosphorylation in the juxtamembrane region of the insulin receptor. J. Biol. Chem., 268, 11256–11264.
3.Stevan R Hubbard (1997). Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. The EMBO Journal., 16(18), 5573–5581.
4.White MF & Kahn CR (1994). The insulin signalling system . J. Biol. Chem., 269, 1-4.
5.NE Block and MG Buse (1989). Effects of hypercortisolemia and diabetes on skeletal muscle insulin receptor function in vitro and in vivo. Am. J. Physiol. Endocrino.l Metab., 256, E39-E48.
6.Dorota B. Schranz, Arif MK Rohilla, Celia Anderson, William M Wood and Paulos Berhanu (1996). Insulin Internalization in the Absence of the Insulin Receptor Tyrosine Kinase Domain Is Insufficient for Mediating Intracellular Biological Effects.
IL Receptor Antagonists
Definition
IL-1R antagonist (IL-1Ra) is a naturally occurring cytokine that competitively inhibits binding of IL-1 and IL-1ß to IL-1Rs without exhibiting detectable agonist activity.
Discovery
The molecule now known as IL- 1ra was first reported in 1985 as an IL- I inhibitory bioactivity of22-25 kD in the supernatants of human monocytes cultured on adherent IgG1. Dayer and colleagues independently reported studies on an IL- inhibitor of similar size in the urine of patients with fever or myelomonocytic leukemia, established that the 22-kD inhibitor semipurified from urine specifically blocked binding of 125I-IL-la to IL-I receptors on the murine thymoma cell line EL4-62.
Structural Characteristics
IL-1Ra exists as two well-characterized forms. Secretory IL-1Ra (sIL-1Ra) and intracellular IL-1Ra (icIL-1Ra) are distinct peptide products of the same IL-1Ra gene, resulting from different first exons and alternative RNA splicing. Thus, sIL-1Ra and icIL-1Ra have different mRNAs with unique transcriptional regulatory regions. sIL-1Ra is translated with a leader sequence, promptly processed to a 17-kDa peptide, glycosylated, and secreted by cells as a 22- to 25-kDa species3. The sIL-1Ra is produced by monocytes, macrophages, neutrophils, fibroblasts, and hepatocytes. The icIL-1Ra is an 18-kDa peptide that lacks a leader sequence, is not glycosylated, and remains within the intracellular space in all systems studied to date.
A third, 16-kDa IL-1Ra isoform has been observed by Western blot analysis within a variety of human cells, including keratinocytes, corneal epithelial and stromal cells,143-amino acid intracellular protein derived by alternative translation initiation from either sIL-1Ra mRNA or icIL-1Ra mRNA4.
Mode of action
IL- I ra appears to be a pure receptor antagonist, binding to IL-I receptors but not activating target cells. Human IL- I ra binds to the type I IL-I receptor on murine EL4-6.1 cells with an affinity of 150 pM, equal to the binding of human IL-la and IL- 1b(25). Furthermore, IL-Ira does not induce receptor interiorization after binding to EL4-6. 1 cells and fails to activate the protein kinase responsible for down-modulation of the epidermal growth factor receptor5.
Functions
Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro - Clinical and experimental evidence suggests that shock, arthritis, osteoporosis, colitis, leukemia, diabetes, wasting and atherosclerosis are mediated, in part, by interleukin 1 (IL-1). Inhibition of this cytokine has been a strategy for studying disease and for new drug development. A naturally-occurring IL-1 inhibitor (IL-1 receptor antagonist, IL-1ra) that blocks binding of IL-1 to its receptors has been cloned and produced in recombinant organisms. IL-1ra reduces the severity of sepsis, colitis, arthritis and diabetes in animals and is presently being tested in humans with arthritis, shock and myelogenous leukemia6.
IL-1 Receptor Antagonist: Role in Biology - Studies in transgenic and knockout mice indicate that IL-1Ra is important in host defense against endotoxin-induced injury. IL-1Ra is produced by hepatic cells with the characteristics of an acute phase protein. Endogenous IL-1Ra is produced in numerous experimental animal models of disease as well as in human autoimmune and chronic inflammatory diseases. The use of neutralizing anti-IL-1Ra antibodies has demonstrated that endogenous IL-1Ra is an important natural antiinflammatory protein in arthritis, colitis, and granulomatous pulmonary disease. Treatment of human diseases with recombinant human IL-1Ra showed an absence of benefit in sepsis syndrome. However, patients with rheumatoid arthritis treated with IL-1Ra for six months exhibited improvements in clinical parameters and in radiographic evidence of joint damage7.
The roles of IL-1 receptor antagonist in skin wound healing- A study showed that healing processes in mice deficient in IL-1 receptor antagonist (IL-1ra), was delayed along with attenuated collagen accumulation in IL-1ra knockout (KO) mice, compared with wild-type (WT) mice. On the contrary, leukocyte recruitment was exaggerated with augmented IL-1 expression in IL-1ra KO mice, implying that IL-1ra deficiency enhanced local inflammatory reaction at the wound sites. Consistently, nuclear translocation of a pro-inflammatory transcription factor, NF-?B, was significantly enhanced and prolonged in fibroblasts in IL-1ra KO mice, compared with WT mice. Previous in vitro observations demonstrated that NF-?B activation could attenuate transforming growth factor (TGF)-ß/Smad signaling pathway, which has crucial roles for collagen deposition in wound healing processes. Indeed, in IL-1ra KO mice; the TGF-ß/Smad signaling pathway was suppressed as evidenced by decreases in phosphorylated Smad2/3 and a reciprocal increase in Smad7 at the wound sites, compared with WT mice. This implied that the absence of IL-1ra resulted in aberrant NF-?B activation and reciprocal diminution in TGF-ß/Smad signaling and eventually attenuated collagen deposition during skin wound healing in vivo8.
References
1.Arend WP, FG Joslin and RJ Massoni (1985). Effects of immune complexes on production by human monocytes of interleukin 1 oran interleukin 1 inhibitor. J. Immunol., 134, 3868-3875.
2.Balavoine JF, B Rochemonteix, K Williamson, P Seckinger, A Cruchaud, and JM. Dayer (1986). Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s). J. Clin. Invest., 78, 1120-1124.
3.Haskill S, Martin G, Van Le L, Morris J, Peace A, Bigler CF, Jaffe GF, Hammerberg C, Sporn SA, Fong S, Arend WP, Ralph P (1991). cDNA cloning of an intracellular form of the human interleukin-1 receptor antagonist associated with epithelium. Proc. Natl. Acad. Sci., 88, 3681.
4.Malyak M, Guthridge JM,, Hance KR, Dower SK, Freedand JH, Arend WP (1998). Characterization of a Low Molecular Weight Isoform of IL-1 Receptor Antagonist. J Immunol.,, 161, 1997-2003.
5.Dripps DJ, Brandhuber BJ, Thompson RC, and Eisenberg SP (1991). Interleukin-l (IL-1) receptor antagonist binds to the 80-kDa IL-I receptor but does not initiate IL-I signal transduction. J. Biol. Chem., 266, 10331-10336.
6.Dinarello CA, Thompson RC (1991). Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol. Today, 12(11), 404-10.
7.Arend WP, Malyak M, Guthridge CJ and Gabay C (1998). INTERLEUKIN-1 RECEPTOR ANTAGONIST: Role in Biology. Annual Review of Immunology, 16, 27-55.
8.Ishida Y, Mukaida N and Kondo K (2008). The roles of IL-1 receptor antagonist in skin wound healing. Inflammation and Regeneration, 28, 31-35.
IL-1R antagonist (IL-1Ra) is a naturally occurring cytokine that competitively inhibits binding of IL-1 and IL-1ß to IL-1Rs without exhibiting detectable agonist activity.
Discovery
The molecule now known as IL- 1ra was first reported in 1985 as an IL- I inhibitory bioactivity of22-25 kD in the supernatants of human monocytes cultured on adherent IgG1. Dayer and colleagues independently reported studies on an IL- inhibitor of similar size in the urine of patients with fever or myelomonocytic leukemia, established that the 22-kD inhibitor semipurified from urine specifically blocked binding of 125I-IL-la to IL-I receptors on the murine thymoma cell line EL4-62.
Structural Characteristics
IL-1Ra exists as two well-characterized forms. Secretory IL-1Ra (sIL-1Ra) and intracellular IL-1Ra (icIL-1Ra) are distinct peptide products of the same IL-1Ra gene, resulting from different first exons and alternative RNA splicing. Thus, sIL-1Ra and icIL-1Ra have different mRNAs with unique transcriptional regulatory regions. sIL-1Ra is translated with a leader sequence, promptly processed to a 17-kDa peptide, glycosylated, and secreted by cells as a 22- to 25-kDa species3. The sIL-1Ra is produced by monocytes, macrophages, neutrophils, fibroblasts, and hepatocytes. The icIL-1Ra is an 18-kDa peptide that lacks a leader sequence, is not glycosylated, and remains within the intracellular space in all systems studied to date.
A third, 16-kDa IL-1Ra isoform has been observed by Western blot analysis within a variety of human cells, including keratinocytes, corneal epithelial and stromal cells,143-amino acid intracellular protein derived by alternative translation initiation from either sIL-1Ra mRNA or icIL-1Ra mRNA4.
Mode of action
IL- I ra appears to be a pure receptor antagonist, binding to IL-I receptors but not activating target cells. Human IL- I ra binds to the type I IL-I receptor on murine EL4-6.1 cells with an affinity of 150 pM, equal to the binding of human IL-la and IL- 1b(25). Furthermore, IL-Ira does not induce receptor interiorization after binding to EL4-6. 1 cells and fails to activate the protein kinase responsible for down-modulation of the epidermal growth factor receptor5.
Functions
Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro - Clinical and experimental evidence suggests that shock, arthritis, osteoporosis, colitis, leukemia, diabetes, wasting and atherosclerosis are mediated, in part, by interleukin 1 (IL-1). Inhibition of this cytokine has been a strategy for studying disease and for new drug development. A naturally-occurring IL-1 inhibitor (IL-1 receptor antagonist, IL-1ra) that blocks binding of IL-1 to its receptors has been cloned and produced in recombinant organisms. IL-1ra reduces the severity of sepsis, colitis, arthritis and diabetes in animals and is presently being tested in humans with arthritis, shock and myelogenous leukemia6.
IL-1 Receptor Antagonist: Role in Biology - Studies in transgenic and knockout mice indicate that IL-1Ra is important in host defense against endotoxin-induced injury. IL-1Ra is produced by hepatic cells with the characteristics of an acute phase protein. Endogenous IL-1Ra is produced in numerous experimental animal models of disease as well as in human autoimmune and chronic inflammatory diseases. The use of neutralizing anti-IL-1Ra antibodies has demonstrated that endogenous IL-1Ra is an important natural antiinflammatory protein in arthritis, colitis, and granulomatous pulmonary disease. Treatment of human diseases with recombinant human IL-1Ra showed an absence of benefit in sepsis syndrome. However, patients with rheumatoid arthritis treated with IL-1Ra for six months exhibited improvements in clinical parameters and in radiographic evidence of joint damage7.
The roles of IL-1 receptor antagonist in skin wound healing- A study showed that healing processes in mice deficient in IL-1 receptor antagonist (IL-1ra), was delayed along with attenuated collagen accumulation in IL-1ra knockout (KO) mice, compared with wild-type (WT) mice. On the contrary, leukocyte recruitment was exaggerated with augmented IL-1 expression in IL-1ra KO mice, implying that IL-1ra deficiency enhanced local inflammatory reaction at the wound sites. Consistently, nuclear translocation of a pro-inflammatory transcription factor, NF-?B, was significantly enhanced and prolonged in fibroblasts in IL-1ra KO mice, compared with WT mice. Previous in vitro observations demonstrated that NF-?B activation could attenuate transforming growth factor (TGF)-ß/Smad signaling pathway, which has crucial roles for collagen deposition in wound healing processes. Indeed, in IL-1ra KO mice; the TGF-ß/Smad signaling pathway was suppressed as evidenced by decreases in phosphorylated Smad2/3 and a reciprocal increase in Smad7 at the wound sites, compared with WT mice. This implied that the absence of IL-1ra resulted in aberrant NF-?B activation and reciprocal diminution in TGF-ß/Smad signaling and eventually attenuated collagen deposition during skin wound healing in vivo8.
References
1.Arend WP, FG Joslin and RJ Massoni (1985). Effects of immune complexes on production by human monocytes of interleukin 1 oran interleukin 1 inhibitor. J. Immunol., 134, 3868-3875.
2.Balavoine JF, B Rochemonteix, K Williamson, P Seckinger, A Cruchaud, and JM. Dayer (1986). Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s). J. Clin. Invest., 78, 1120-1124.
3.Haskill S, Martin G, Van Le L, Morris J, Peace A, Bigler CF, Jaffe GF, Hammerberg C, Sporn SA, Fong S, Arend WP, Ralph P (1991). cDNA cloning of an intracellular form of the human interleukin-1 receptor antagonist associated with epithelium. Proc. Natl. Acad. Sci., 88, 3681.
4.Malyak M, Guthridge JM,, Hance KR, Dower SK, Freedand JH, Arend WP (1998). Characterization of a Low Molecular Weight Isoform of IL-1 Receptor Antagonist. J Immunol.,, 161, 1997-2003.
5.Dripps DJ, Brandhuber BJ, Thompson RC, and Eisenberg SP (1991). Interleukin-l (IL-1) receptor antagonist binds to the 80-kDa IL-I receptor but does not initiate IL-I signal transduction. J. Biol. Chem., 266, 10331-10336.
6.Dinarello CA, Thompson RC (1991). Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol. Today, 12(11), 404-10.
7.Arend WP, Malyak M, Guthridge CJ and Gabay C (1998). INTERLEUKIN-1 RECEPTOR ANTAGONIST: Role in Biology. Annual Review of Immunology, 16, 27-55.
8.Ishida Y, Mukaida N and Kondo K (2008). The roles of IL-1 receptor antagonist in skin wound healing. Inflammation and Regeneration, 28, 31-35.
Hirudin Fragments and Analogs
Definition
Hirudin is a thrombin-specific inhibitor isolated from the leech Hirudo medicinalis
Hirudin analogs
CX-397 is novel recombinant hirudin analog, composed of the N-terminal half of HV-1 (HV-11-36) combined with the C-terminal half of HV-3 (HV-337-66). Bivalirudin, a synthetic analog of the carboxy-terminus of hirudin, is a reversible thrombin inhibitor.
Structural Characteristics
The thrombin-specific inhibitor hirudin is a polypeptide of 65 or 66 amino acid residues isolated from the leech Hirudo medicinalis. Sequence analysis of different naturally occurring forms of hirudin revealed homologies 80%. The 6 cysteine residues of three disulfide bonds connecting Cys6with Cys14, Cys16 with Cys28, and Cys22 with Cys39 has also been detected. Hirudin consists of an amino-terminal compact domain (residues l-49) held together by the three disulfide linkages and a distorted carboxyl-terminal tail (residues 50- 65) which does not fold back on the rest of the protein. Hirudin reacts rapidly with a-thrombin forming tight, noncovalent 1. The specificity of the interaction of a-thrombin with macromolecular substrates is assumed to reside in interactions at three distinct regions: the primary binding pocket for the P1 residue, an apolar binding site adjacent to the catalytic site, and an anion-binding region which may be responsible for the specific interaction of thrombin with fibrinogen2.
Mode of Action
The hirudin acts as a potent anticoagulant by binding to thrombin with high specificity and affinity. Hirudin is distinguished from conventional protease inhibitors by two unique characteristics. (a) Unlike most protease inhibitors which contain a well-defined reactive site (P1 residue) that interacts with the active site of the target enzyme1. The structural element of hirudin which blocks the active site of thrombin is an extended hydrophobic site including the Hz-terminal residues (Val1, Val2, and Tyr3)3. (b) Unlike most serine protease inhibitors which are compact molecules, hirudin has a tadpole-like shape, consisting of a compact amino-terminal domain and a disordered carboxyl-terminal tail4.
Functions
CX-397, a novel recombinant hirudin analog - A study was conducted using four hirudin analogs in thrombin inhibition, which included CX-397, CX-397R, hirudin variants-1 (HV-11-36) and -3 (HV-337-366).Their anti-thrombin activity was determined by a fluorogenic enzyme assay and compared with that of recombinant HV-1 (rHV-1) and rHV-3. The order of the magnitude of dissociation constants (Ki) of these four hirudin analogs in thrombin inhibition was as follows: CX-397R (0.294 pM) > rHV-1 (0.148 pM) > rHV-3 (0.0593 pM) > CX-397 (0.0433 pM), indicating that CX-397 is the strongest inhibitor among them5.
Reduction of adhesion formation by intraperitoneal administration of a recombinant Hirudin analog - Adhesion formation is a major source of postoperative morbidity and mortality. Therefore, the reduction of postoperative adhesion formation would be of clinical benefit. Various modalities have been shown to reduce adhesion formation, including fibrinolytic enzymes, nonsteroidal anti-inflammatory drugs, and barriers that reduce the apposition of sites of potential adhesion formation. A study was conducted to examine the ability of an inhibitor of thrombin, a recombinant hirudin analog (recHirudin), to reduce the formation of intraperitoneal adhesions in two rabbit models of adhesion formation. In the sidewall and double uterine horn models, recHirudin was administered via Alzet miniosmotic pump for the entire postoperative interval. In both of these models, there was a dose-dependent reduction in adhesion formation as measured by (1) the area of the sidewall injury that was involved in adhesions to the cecum and the bowel or (2) the involvement of the uterine horns to themselves or other peritoneal organs. This implies that postoperative administration of recHirudin to the site of injury reduced the formation of postoperative adhesions in two animal models6.
Influence of bivalirudin on tissue factor-triggered coagulation - Bivalirudin, a synthetic analog of the carboxy-terminus of hirudin, is a reversible thrombin inhibitor. A study was conducted using three in-vitro models (numerical simulations, synthetic coagulation proteome and whole blood) of contact pathway-independent blood coagulation triggered with tissue factor. It was found that increasing concentrations of bivalirudin prolong the initiation phase of thrombin generation in a concentration-dependent manner. At subpharmacologic bivalirudin concentrations (0.5-2 micromol/l), total thrombin generation was significantly increased. At a pharmacologic concentration (5 micromol/l), bivalirudin suppressed thrombin generation in the synthetic coagulation proteome; in numerical simulations and contact pathway-inhibited whole blood, no thrombin generation was detected over 1200-2000 s and platelet activation was inhibited by 80%. The addition of a pharmacologic concentration (9 micromol/l) of a naturally occurring protease inhibitor aprotinin in the presence of at least 0.5 micromol/l bivalirudin provided limited enhancement of the bivalirudin inhibitory effect. This implied that bivalirudin at pharmacologic concentrations is an efficient inhibitor of thrombin generation, platelet activation and clot formation, which acts not as a modulator but as an 'on-off' switch of blood coagulation7.
References
1.Dodt J, Seemüller U, Maschler R, Fritz H (1985). The complete covalent structure of hirudin: Localization of the disulfide bonds. Biol. Chem. Hoppe. Seyler., 366(4), 379-85.
2.John W. Fenton , Frederick A. Ofosu, Diane V. Brezniak, Houria I. Hassouna (1998).Thrombin and Antithrombotics. Semin. Thromb. Hemost., 24, 87-91.
3.TJ Rydel, KG Ravichandran, A Tulinsky, W Bode, R Huber, C Roitsch, and JW Fenton 2nd (1990). The structure of a complex of recombinant hirudin and human alpha-thrombin. Science., 249 (4966), 277-280.
4.Chang JY (1983).The functional domain of hirudin, a thrombin-specific inhibitor. FEBS Lett., 164(2), 307-13.
5.Komatsu Y, Misawa S, Sukesada A, Ohba Y, Hayashi H (1993). CX-397, a novel recombinant hirudin analog having a hybrid sequence of hirudin variants-1 and -3. Biochem. Biophys. Res. Commun., 196(2), 773-9.
6.Rodgers KE, Girgis W, Campeau JD, diZerega GS (1996). Reduction of adhesion formation by intraperitoneal administration of a recombinant Hirudin analog. J. Invest. Surg ., (5), 385-91.
7.Butenas S, Orfeo T, Brummel-Ziedins KE, Mann KG. 2007 Influence of bivalirudin on tissue factor-triggered coagulation. Blood Coagul Fibrinolysis., 18(5), 407-14.
Hirudin is a thrombin-specific inhibitor isolated from the leech Hirudo medicinalis
Hirudin analogs
CX-397 is novel recombinant hirudin analog, composed of the N-terminal half of HV-1 (HV-11-36) combined with the C-terminal half of HV-3 (HV-337-66). Bivalirudin, a synthetic analog of the carboxy-terminus of hirudin, is a reversible thrombin inhibitor.
Structural Characteristics
The thrombin-specific inhibitor hirudin is a polypeptide of 65 or 66 amino acid residues isolated from the leech Hirudo medicinalis. Sequence analysis of different naturally occurring forms of hirudin revealed homologies 80%. The 6 cysteine residues of three disulfide bonds connecting Cys6with Cys14, Cys16 with Cys28, and Cys22 with Cys39 has also been detected. Hirudin consists of an amino-terminal compact domain (residues l-49) held together by the three disulfide linkages and a distorted carboxyl-terminal tail (residues 50- 65) which does not fold back on the rest of the protein. Hirudin reacts rapidly with a-thrombin forming tight, noncovalent 1. The specificity of the interaction of a-thrombin with macromolecular substrates is assumed to reside in interactions at three distinct regions: the primary binding pocket for the P1 residue, an apolar binding site adjacent to the catalytic site, and an anion-binding region which may be responsible for the specific interaction of thrombin with fibrinogen2.
Mode of Action
The hirudin acts as a potent anticoagulant by binding to thrombin with high specificity and affinity. Hirudin is distinguished from conventional protease inhibitors by two unique characteristics. (a) Unlike most protease inhibitors which contain a well-defined reactive site (P1 residue) that interacts with the active site of the target enzyme1. The structural element of hirudin which blocks the active site of thrombin is an extended hydrophobic site including the Hz-terminal residues (Val1, Val2, and Tyr3)3. (b) Unlike most serine protease inhibitors which are compact molecules, hirudin has a tadpole-like shape, consisting of a compact amino-terminal domain and a disordered carboxyl-terminal tail4.
Functions
CX-397, a novel recombinant hirudin analog - A study was conducted using four hirudin analogs in thrombin inhibition, which included CX-397, CX-397R, hirudin variants-1 (HV-11-36) and -3 (HV-337-366).Their anti-thrombin activity was determined by a fluorogenic enzyme assay and compared with that of recombinant HV-1 (rHV-1) and rHV-3. The order of the magnitude of dissociation constants (Ki) of these four hirudin analogs in thrombin inhibition was as follows: CX-397R (0.294 pM) > rHV-1 (0.148 pM) > rHV-3 (0.0593 pM) > CX-397 (0.0433 pM), indicating that CX-397 is the strongest inhibitor among them5.
Reduction of adhesion formation by intraperitoneal administration of a recombinant Hirudin analog - Adhesion formation is a major source of postoperative morbidity and mortality. Therefore, the reduction of postoperative adhesion formation would be of clinical benefit. Various modalities have been shown to reduce adhesion formation, including fibrinolytic enzymes, nonsteroidal anti-inflammatory drugs, and barriers that reduce the apposition of sites of potential adhesion formation. A study was conducted to examine the ability of an inhibitor of thrombin, a recombinant hirudin analog (recHirudin), to reduce the formation of intraperitoneal adhesions in two rabbit models of adhesion formation. In the sidewall and double uterine horn models, recHirudin was administered via Alzet miniosmotic pump for the entire postoperative interval. In both of these models, there was a dose-dependent reduction in adhesion formation as measured by (1) the area of the sidewall injury that was involved in adhesions to the cecum and the bowel or (2) the involvement of the uterine horns to themselves or other peritoneal organs. This implies that postoperative administration of recHirudin to the site of injury reduced the formation of postoperative adhesions in two animal models6.
Influence of bivalirudin on tissue factor-triggered coagulation - Bivalirudin, a synthetic analog of the carboxy-terminus of hirudin, is a reversible thrombin inhibitor. A study was conducted using three in-vitro models (numerical simulations, synthetic coagulation proteome and whole blood) of contact pathway-independent blood coagulation triggered with tissue factor. It was found that increasing concentrations of bivalirudin prolong the initiation phase of thrombin generation in a concentration-dependent manner. At subpharmacologic bivalirudin concentrations (0.5-2 micromol/l), total thrombin generation was significantly increased. At a pharmacologic concentration (5 micromol/l), bivalirudin suppressed thrombin generation in the synthetic coagulation proteome; in numerical simulations and contact pathway-inhibited whole blood, no thrombin generation was detected over 1200-2000 s and platelet activation was inhibited by 80%. The addition of a pharmacologic concentration (9 micromol/l) of a naturally occurring protease inhibitor aprotinin in the presence of at least 0.5 micromol/l bivalirudin provided limited enhancement of the bivalirudin inhibitory effect. This implied that bivalirudin at pharmacologic concentrations is an efficient inhibitor of thrombin generation, platelet activation and clot formation, which acts not as a modulator but as an 'on-off' switch of blood coagulation7.
References
1.Dodt J, Seemüller U, Maschler R, Fritz H (1985). The complete covalent structure of hirudin: Localization of the disulfide bonds. Biol. Chem. Hoppe. Seyler., 366(4), 379-85.
2.John W. Fenton , Frederick A. Ofosu, Diane V. Brezniak, Houria I. Hassouna (1998).Thrombin and Antithrombotics. Semin. Thromb. Hemost., 24, 87-91.
3.TJ Rydel, KG Ravichandran, A Tulinsky, W Bode, R Huber, C Roitsch, and JW Fenton 2nd (1990). The structure of a complex of recombinant hirudin and human alpha-thrombin. Science., 249 (4966), 277-280.
4.Chang JY (1983).The functional domain of hirudin, a thrombin-specific inhibitor. FEBS Lett., 164(2), 307-13.
5.Komatsu Y, Misawa S, Sukesada A, Ohba Y, Hayashi H (1993). CX-397, a novel recombinant hirudin analog having a hybrid sequence of hirudin variants-1 and -3. Biochem. Biophys. Res. Commun., 196(2), 773-9.
6.Rodgers KE, Girgis W, Campeau JD, diZerega GS (1996). Reduction of adhesion formation by intraperitoneal administration of a recombinant Hirudin analog. J. Invest. Surg ., (5), 385-91.
7.Butenas S, Orfeo T, Brummel-Ziedins KE, Mann KG. 2007 Influence of bivalirudin on tissue factor-triggered coagulation. Blood Coagul Fibrinolysis., 18(5), 407-14.
High Mobility Group (HMG) Peptide
Definition
The high mobility group (HMG) proteins are a superfamily of abundant and ubiquitous nuclear proteins that bind to DNA and nucleosomes and induce structural changes in the chromatin fiber.
Discovery
An early report showed that non-histone chromosomal proteins NHCP extracted with 0.35 M NaCl from calf thymus chromatin can be fractionated into two main groups by trichloroacetic acid precipitation. These groups were named on the basis of their respective mobilities in 20% polyacrylamide gels at pH 2.4. The NHCP with low electrophoretic mobilities were called low mobility group (LMG) proteins and those with high electrophoretic mobilities were named high mobility group (HMG) proteins1.
Structural Characteristics
The HMG protein family consists of six proteins and is subdivided into three subfamilies: the HMG-1/-2 subfamily, the HMG-I/Y subfamily and the HMG-14/-17 subfamily. The HMG-1 domain (often referred to as the HMG-1 box) is the functional motif of the largest HMG subfamily, the HMG-1/-2 proteins; the AT hook is the functional motif of the HMG-I/Y group, and the nucleosomal binding domain is the functional motif of the HMG-14/-17 subfamily.
The HMG-1 domain consists of approximately 80 amino acids and has a characteristic, twisted, L-shaped fold formed by three -helical segments2.
The AT hook motif is a positively charged stretch of 9 amino acids containing the invariant tripeptide GlyArgPro (GRP), usually flanked by arginine residues3.
The nucleosomal binding domain motif HMG-14 and HMG-17 protein is a positively charged stretch of approximately 30 amino acids with a bipartite structure: the amino-terminal region is extremely conserved and enriched in arginine residues, while the carboxyl-terminal region is highly enriched in lysine and proline residues4.
Mode of Action
The HMG-1 domain binds to and bends the minor groove of the DNA- The HMG-1 domain binds the DNA exclusively through the minor groove. A wedge of hydrophobic amino acids protruding from the concave surface of the protein partially intercalates between the DNA bases, expanding the minor groove, thereby significantly unwinding and bending the DNA. The amino acid sequence in the helical regions of the L-shaped HMG-1 domain provides specificity in DNA binding, while the type of intercalating amino acids and the angle of the L-shaped fold affect the degree to which the DNA is unwound and bent2.
The AT hook tethers proteins to and unbends the minor groove of the DNA The AT hook binds to the DNA through the minor groove with the optimal DNA binding site centered at the sequence AA(T/A)T. The AT hook has a narrow DNA recognition surface which is devoid of hydrophobic amino acids and does not significantly distort the B-form DNA structure3.
The nucleosomal binding domain anchors HMG-14 and HMG-17 proteins to nucleosomes The two proteins bind to nucleosomes cooperatively and form complexes containing either two molecules of HMG-14 or two molecules of HMG-17 but not complexes containing one molecule of each protein. The main function of these proteins is to change the architecture of the higher-order chromatin structure, mediated through the C-terminal region of the proteins. The nucleosomal binding domain anchors these HMG proteins to the nucleosome cores to facilitate HMG-14/-17-dependent changes in chromatin structure4.
Functions
High mobility group protein-1 (HMG-1) is a unique activator of p53 –A study showed that a HMG-1 factor from HeLa nuclear extracts activated p53 DNA binding. It was also demonstrated that recombinant His-tagged HMG-1 enhances p53 DNA binding in vitro and also that HMG-1 and p53 can interact directly in vitro. Further it has been shown that, HMG-1 also stimulates DNA binding by p53D30, a carboxy-terminally deleted form of the protein that is considered to be constitutively active, suggesting that HMG-1 stimulates p53 by a mechanism that is distinct from other known p53 activators5.
High Mobility Group Proteins 14 and 17 Can Prevent the Close Packing of Nucleosomes by Increasing the Strength of Protein Contacts in the Linker DNA - A study shows that digestion of HMG containing chromatin with micrococcal nuclease produces DNA fragments that were approximately 10 and 20 base pairs longer than nucleosome core-particle DNA. This suggests that HMG 14 or HMG 17 can protect, directly or indirectly, at least an additional 10 base pairs of linker DNA from micrococcal digestion. Also there is evidence that extensive micrococcal nuclease digestion of chromatin deficient in histones H2A/H2B led to the accumulation of DNA fragments about 110 base pairs in length, which is presumably the length of DNA associated with a nucleosomal particle deficient in one H2A/H2B dimer. Incorporation of either HMG 14 or HMG 17 into this chromatin results in the disappearance of this band and increase in the accumulation of fragments around 140-150 base pairs in length. In contrast to spacing of complete nucleosomes, it was found that the nucleosome binding domain of HMG 17 (but not the nucleosome binding of HMG 14) is the only domain required for spacing of H2A/H2B-deficient chromatin6.
References
1.Goodwin G (1998). The high mobility group protein, HMGI-C. Int. J. Biochem. Cell Biol., 30, 761-766.
2.Bustin M, and R Reeves (1996). High mobility group chromosomal proteins: architectural components that facilitate chromatin function. Prog. Nucleic Acid Res. Mol. Biol., 54, 35-100.
3.Aravind L and D Landsman (1998). AT-hook motifs identified in a wide variety of DNA-binding proteins. Nucleic Acids Res., 26, 4413-4421
4.Postnikov YV, L Trieschmann, Rickers, and Bustin (1995). Homodimers of chromosomal proteins HMG-14 and HMG-17 in nucleosome cores. J. Mol. Biol. 252, 423-432.
5.Lata Jayaraman, Narayani Chandra Moorthy, Kanneganti GK. Murthy, et al. (1998). High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev., 12, 462-472.
6.Bernard Degryse , Tiziana Bonaldi , Paola Scaffidi , Susanne Müller , Massimo Resnati , Francesca Sanvito , Gianluigi Arrigoni , and Marco E Bianchi (2001). High Mobility Group Proteins 14 and 17 Can Prevent the Close Packing of Nucleosomes by Increasing the Strength of Protein Contacts in the Linker DNA. The Journal of Cell Biology., 52(6), 1197-1206.
The high mobility group (HMG) proteins are a superfamily of abundant and ubiquitous nuclear proteins that bind to DNA and nucleosomes and induce structural changes in the chromatin fiber.
Discovery
An early report showed that non-histone chromosomal proteins NHCP extracted with 0.35 M NaCl from calf thymus chromatin can be fractionated into two main groups by trichloroacetic acid precipitation. These groups were named on the basis of their respective mobilities in 20% polyacrylamide gels at pH 2.4. The NHCP with low electrophoretic mobilities were called low mobility group (LMG) proteins and those with high electrophoretic mobilities were named high mobility group (HMG) proteins1.
Structural Characteristics
The HMG protein family consists of six proteins and is subdivided into three subfamilies: the HMG-1/-2 subfamily, the HMG-I/Y subfamily and the HMG-14/-17 subfamily. The HMG-1 domain (often referred to as the HMG-1 box) is the functional motif of the largest HMG subfamily, the HMG-1/-2 proteins; the AT hook is the functional motif of the HMG-I/Y group, and the nucleosomal binding domain is the functional motif of the HMG-14/-17 subfamily.
The HMG-1 domain consists of approximately 80 amino acids and has a characteristic, twisted, L-shaped fold formed by three -helical segments2.
The AT hook motif is a positively charged stretch of 9 amino acids containing the invariant tripeptide GlyArgPro (GRP), usually flanked by arginine residues3.
The nucleosomal binding domain motif HMG-14 and HMG-17 protein is a positively charged stretch of approximately 30 amino acids with a bipartite structure: the amino-terminal region is extremely conserved and enriched in arginine residues, while the carboxyl-terminal region is highly enriched in lysine and proline residues4.
Mode of Action
The HMG-1 domain binds to and bends the minor groove of the DNA- The HMG-1 domain binds the DNA exclusively through the minor groove. A wedge of hydrophobic amino acids protruding from the concave surface of the protein partially intercalates between the DNA bases, expanding the minor groove, thereby significantly unwinding and bending the DNA. The amino acid sequence in the helical regions of the L-shaped HMG-1 domain provides specificity in DNA binding, while the type of intercalating amino acids and the angle of the L-shaped fold affect the degree to which the DNA is unwound and bent2.
The AT hook tethers proteins to and unbends the minor groove of the DNA The AT hook binds to the DNA through the minor groove with the optimal DNA binding site centered at the sequence AA(T/A)T. The AT hook has a narrow DNA recognition surface which is devoid of hydrophobic amino acids and does not significantly distort the B-form DNA structure3.
The nucleosomal binding domain anchors HMG-14 and HMG-17 proteins to nucleosomes The two proteins bind to nucleosomes cooperatively and form complexes containing either two molecules of HMG-14 or two molecules of HMG-17 but not complexes containing one molecule of each protein. The main function of these proteins is to change the architecture of the higher-order chromatin structure, mediated through the C-terminal region of the proteins. The nucleosomal binding domain anchors these HMG proteins to the nucleosome cores to facilitate HMG-14/-17-dependent changes in chromatin structure4.
Functions
High mobility group protein-1 (HMG-1) is a unique activator of p53 –A study showed that a HMG-1 factor from HeLa nuclear extracts activated p53 DNA binding. It was also demonstrated that recombinant His-tagged HMG-1 enhances p53 DNA binding in vitro and also that HMG-1 and p53 can interact directly in vitro. Further it has been shown that, HMG-1 also stimulates DNA binding by p53D30, a carboxy-terminally deleted form of the protein that is considered to be constitutively active, suggesting that HMG-1 stimulates p53 by a mechanism that is distinct from other known p53 activators5.
High Mobility Group Proteins 14 and 17 Can Prevent the Close Packing of Nucleosomes by Increasing the Strength of Protein Contacts in the Linker DNA - A study shows that digestion of HMG containing chromatin with micrococcal nuclease produces DNA fragments that were approximately 10 and 20 base pairs longer than nucleosome core-particle DNA. This suggests that HMG 14 or HMG 17 can protect, directly or indirectly, at least an additional 10 base pairs of linker DNA from micrococcal digestion. Also there is evidence that extensive micrococcal nuclease digestion of chromatin deficient in histones H2A/H2B led to the accumulation of DNA fragments about 110 base pairs in length, which is presumably the length of DNA associated with a nucleosomal particle deficient in one H2A/H2B dimer. Incorporation of either HMG 14 or HMG 17 into this chromatin results in the disappearance of this band and increase in the accumulation of fragments around 140-150 base pairs in length. In contrast to spacing of complete nucleosomes, it was found that the nucleosome binding domain of HMG 17 (but not the nucleosome binding of HMG 14) is the only domain required for spacing of H2A/H2B-deficient chromatin6.
References
1.Goodwin G (1998). The high mobility group protein, HMGI-C. Int. J. Biochem. Cell Biol., 30, 761-766.
2.Bustin M, and R Reeves (1996). High mobility group chromosomal proteins: architectural components that facilitate chromatin function. Prog. Nucleic Acid Res. Mol. Biol., 54, 35-100.
3.Aravind L and D Landsman (1998). AT-hook motifs identified in a wide variety of DNA-binding proteins. Nucleic Acids Res., 26, 4413-4421
4.Postnikov YV, L Trieschmann, Rickers, and Bustin (1995). Homodimers of chromosomal proteins HMG-14 and HMG-17 in nucleosome cores. J. Mol. Biol. 252, 423-432.
5.Lata Jayaraman, Narayani Chandra Moorthy, Kanneganti GK. Murthy, et al. (1998). High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev., 12, 462-472.
6.Bernard Degryse , Tiziana Bonaldi , Paola Scaffidi , Susanne Müller , Massimo Resnati , Francesca Sanvito , Gianluigi Arrigoni , and Marco E Bianchi (2001). High Mobility Group Proteins 14 and 17 Can Prevent the Close Packing of Nucleosomes by Increasing the Strength of Protein Contacts in the Linker DNA. The Journal of Cell Biology., 52(6), 1197-1206.
Helodermins
Definition
Helodermin is a peptide that shows a high degree of sequence similarity with vasoactive intestinal peptide (VIP), peptide histidine isoleucine (PHI) and secretin in its N-terminal moiety.
Discovery
In 1982, it was observed that the venom from Gila monster exerts a potent secretory effect on dispersed pancreatic acini from guinea pig. Moreover, the venom causes a 50-fold increase in increase in cellular cAMP and inhibited binding of 125I-vasoactive intestinal peptide to its membrane receptors on pancreatic acini. These results indicate that venom from Gila monster contains a peptide helodermin, which can stimulate pancreatic enzyme secretion by interacting with vasoactive intestinal peptide receptors on pancreatic acinar cells and thereby activating adenylate cyclase and increasing cellular cAMP1.
Structural Characteristics
The complete amino acid sequence of helodermin isolated from the venom of Gila monster has been elucidated. The peptide has shown to be a basic pentatriacontapeptide amide: His-Ser-Asp-Ala-Ile-Phe-Thr-Gln-Gln-Tyr-Ser-Lys-Leu-Leu-Ala-Lys-Leu-Ala-Leu-Gln-Lys-Tyr-Leu-Ala-Ser-Ile-Leu-Gly-Ser-Arg-Thr-Ser-Pro-Pro-Pro-NH2. A high degree of sequence similarities to secretin/ VIP/ PHI/ (PHM)/ GRF from mammal and bird was observed over the entire N-terminal 1–27 sequence. Another interesting feature of the structure of helodermin was its C-terminal -Pro-Pro-Pro-NH2 sequence2.
In comparison with other members of the secretin/VIP family of peptides, helodermin has an unusually stable secondary structure, partly owing to a secondary configuration it maintains in water, which may account for its prolonged physiological action 3.
Functions
Helodermin, helospectin, and PACAP stimulate cyclic AMP formation in intact bone, isolated osteoblasts, and osteoblastic cell lines - Helodermin and helospectin isolated from the salivary gland venom of the lizard Heloderma suspectum and Pituitary adenylate cyclaseactivating polypeptide (PACAP) isolated from ovine hypothalamus shows sequence homology to vasoactive intestinal peptide (VIP). In a study, lizard helodermin was found to cause a time- and dose-dependent stimulation of cyclic AMP (cAMP) formation in neonatal mouse calvarial bones. Also, helospectin I, PACAP 27, and the C-terminally extended PACAP 38 stimulated cAMP accumulation in the mouse calvariae. The cAMP rise in response to helodermin was comparable to that induced by VIP, both in terms of potency and magnitude of the response. Helodermin, helospectin I, PACAP 27, and PACAP 38, at concentrations of 1 mol/liter, stimulated cAMP accumulation in enzymatically isolated mouse calvarial bone cells. A significant response to all peptides was observed in both early and late released bone cells isolated from the calvariae, with low and high alkaline phosphatase activity, respectively. Helodermin and VIP stimulated cAMP accumulation in the cloned mouse calvarial osteoblastic cell line MC3T3-E1, in rat (UMR 106-01), and human (Saos-2) osteoblastic osteosarcoma cell lines, but not in the rat osteosarcoma cell line ROS 17/2.8. The effect of helodermin was synergistically and dose-dependently enhanced by forskolin (0.1 and 1 mol/liter). These data show that bone cells, including osteoblasts, respond to several peptides of the VIP family, including helodermin, helospectin I, PACAP 27, and PACAP 38 4.
Helodermin produced Glibenclamide-sensitive hypotension in the rat- The effects of helodermin, on arterial blood pressure and heart rate were examined in the rat, focusing on the possibility that activation of ATP sensitive K+ (K(ATP)) channels is involved in the responses. Helodermin produced hypotension in a dose-dependent manner with approximately similar potency and duration when to compare with those of vasoactive intestinal polypeptide (VIP). These findings suggest that helodermin-produced hypotension is partly attributable to the activation of glibenclamide-sensitive K+ channels (K (ATP) channels), which presumably exist on arterial smooth muscle cells5.
Helodermin-like peptides stimulate thyroid hormone secretion and suppression of calcium incorporation into bone- Helodermin-like immunofluorescence was observed in the parafollicular (C) cells in several mammals and in the C cell homologues of the chicken ultimobranchial gland. Helodermin stimulated basal thyroid hormone secretion and colloid droplet formation in conscious mice. The effect of large doses of helodermin was quite long-lasting and the maximal response occurred after 2 - 6 hr. In addition, helodermin suppressed the incorporation of calcium into bone in conscious rats. These findings suggest that helodermin-like peptides in C cells may be involved in the local regulation of thyroid hormone secretion and in the maintenance of calcium homeostasis6.
References:
1.Raufman, J P, Jensen RT, Sutliff V E., Pisano J J and Gardner J D (1982). Actions of Gila monster venom on dispersed acini from guinea pig pancreas. Am. J. Physiol., 242, G470-G474.
2.Hoshino M, Yanaihara C, Hong Y M, Kishida S, Katsumara Y, Vandermeers A, Vandermeers-Piret M-C, Robberecht P, Christophe J & Yanaihara N (1984). Primary structure of helodermin, a VIP-like peptide isolated from the Gila monster venom. FEBS Lett 178: 233-239.
3.Wulf Blankenfeldt, Kiyoshi Nokihara, Satoru Naruse, Uta Lessel, Dietmar Schomburg, and Victor Wray (1996). NMR Spectroscopic Evidence That Helodermin, unlike Other Members of the Secretin /VIP Family of Peptides, Is Substantially Structured in Water Biochemistry., 35 (19), 5955–5962.
4.U. H. Lerner, P. Lundberg, M. Ransjö, P. Perssonand R (1994). Hakanson Helodermin, helospectin, and PACAP stimulate cyclic AMP formation in intact bone, isolated osteoblasts, and osteoblastic cell lines. Calcified Tissue International., 54: 284-289
5.N Horikawa, K Kataha, N Watanabe, K Ishii, N Yanaihara, Y Tanaka, K Shigenobu, K Nakayama (1998). Biological & pharmaceutical bulletin 21: 1290-3.
6.T Grunditz, P Persson, R Hakanson, A Abosood, G Bottcher, C Rerup and Sundler (1989). Proc. NatI. Acad. Sci., 86: 1357-1361.
Helodermin is a peptide that shows a high degree of sequence similarity with vasoactive intestinal peptide (VIP), peptide histidine isoleucine (PHI) and secretin in its N-terminal moiety.
Discovery
In 1982, it was observed that the venom from Gila monster exerts a potent secretory effect on dispersed pancreatic acini from guinea pig. Moreover, the venom causes a 50-fold increase in increase in cellular cAMP and inhibited binding of 125I-vasoactive intestinal peptide to its membrane receptors on pancreatic acini. These results indicate that venom from Gila monster contains a peptide helodermin, which can stimulate pancreatic enzyme secretion by interacting with vasoactive intestinal peptide receptors on pancreatic acinar cells and thereby activating adenylate cyclase and increasing cellular cAMP1.
Structural Characteristics
The complete amino acid sequence of helodermin isolated from the venom of Gila monster has been elucidated. The peptide has shown to be a basic pentatriacontapeptide amide: His-Ser-Asp-Ala-Ile-Phe-Thr-Gln-Gln-Tyr-Ser-Lys-Leu-Leu-Ala-Lys-Leu-Ala-Leu-Gln-Lys-Tyr-Leu-Ala-Ser-Ile-Leu-Gly-Ser-Arg-Thr-Ser-Pro-Pro-Pro-NH2. A high degree of sequence similarities to secretin/ VIP/ PHI/ (PHM)/ GRF from mammal and bird was observed over the entire N-terminal 1–27 sequence. Another interesting feature of the structure of helodermin was its C-terminal -Pro-Pro-Pro-NH2 sequence2.
In comparison with other members of the secretin/VIP family of peptides, helodermin has an unusually stable secondary structure, partly owing to a secondary configuration it maintains in water, which may account for its prolonged physiological action 3.
Functions
Helodermin, helospectin, and PACAP stimulate cyclic AMP formation in intact bone, isolated osteoblasts, and osteoblastic cell lines - Helodermin and helospectin isolated from the salivary gland venom of the lizard Heloderma suspectum and Pituitary adenylate cyclaseactivating polypeptide (PACAP) isolated from ovine hypothalamus shows sequence homology to vasoactive intestinal peptide (VIP). In a study, lizard helodermin was found to cause a time- and dose-dependent stimulation of cyclic AMP (cAMP) formation in neonatal mouse calvarial bones. Also, helospectin I, PACAP 27, and the C-terminally extended PACAP 38 stimulated cAMP accumulation in the mouse calvariae. The cAMP rise in response to helodermin was comparable to that induced by VIP, both in terms of potency and magnitude of the response. Helodermin, helospectin I, PACAP 27, and PACAP 38, at concentrations of 1 mol/liter, stimulated cAMP accumulation in enzymatically isolated mouse calvarial bone cells. A significant response to all peptides was observed in both early and late released bone cells isolated from the calvariae, with low and high alkaline phosphatase activity, respectively. Helodermin and VIP stimulated cAMP accumulation in the cloned mouse calvarial osteoblastic cell line MC3T3-E1, in rat (UMR 106-01), and human (Saos-2) osteoblastic osteosarcoma cell lines, but not in the rat osteosarcoma cell line ROS 17/2.8. The effect of helodermin was synergistically and dose-dependently enhanced by forskolin (0.1 and 1 mol/liter). These data show that bone cells, including osteoblasts, respond to several peptides of the VIP family, including helodermin, helospectin I, PACAP 27, and PACAP 38 4.
Helodermin produced Glibenclamide-sensitive hypotension in the rat- The effects of helodermin, on arterial blood pressure and heart rate were examined in the rat, focusing on the possibility that activation of ATP sensitive K+ (K(ATP)) channels is involved in the responses. Helodermin produced hypotension in a dose-dependent manner with approximately similar potency and duration when to compare with those of vasoactive intestinal polypeptide (VIP). These findings suggest that helodermin-produced hypotension is partly attributable to the activation of glibenclamide-sensitive K+ channels (K (ATP) channels), which presumably exist on arterial smooth muscle cells5.
Helodermin-like peptides stimulate thyroid hormone secretion and suppression of calcium incorporation into bone- Helodermin-like immunofluorescence was observed in the parafollicular (C) cells in several mammals and in the C cell homologues of the chicken ultimobranchial gland. Helodermin stimulated basal thyroid hormone secretion and colloid droplet formation in conscious mice. The effect of large doses of helodermin was quite long-lasting and the maximal response occurred after 2 - 6 hr. In addition, helodermin suppressed the incorporation of calcium into bone in conscious rats. These findings suggest that helodermin-like peptides in C cells may be involved in the local regulation of thyroid hormone secretion and in the maintenance of calcium homeostasis6.
References:
1.Raufman, J P, Jensen RT, Sutliff V E., Pisano J J and Gardner J D (1982). Actions of Gila monster venom on dispersed acini from guinea pig pancreas. Am. J. Physiol., 242, G470-G474.
2.Hoshino M, Yanaihara C, Hong Y M, Kishida S, Katsumara Y, Vandermeers A, Vandermeers-Piret M-C, Robberecht P, Christophe J & Yanaihara N (1984). Primary structure of helodermin, a VIP-like peptide isolated from the Gila monster venom. FEBS Lett 178: 233-239.
3.Wulf Blankenfeldt, Kiyoshi Nokihara, Satoru Naruse, Uta Lessel, Dietmar Schomburg, and Victor Wray (1996). NMR Spectroscopic Evidence That Helodermin, unlike Other Members of the Secretin /VIP Family of Peptides, Is Substantially Structured in Water Biochemistry., 35 (19), 5955–5962.
4.U. H. Lerner, P. Lundberg, M. Ransjö, P. Perssonand R (1994). Hakanson Helodermin, helospectin, and PACAP stimulate cyclic AMP formation in intact bone, isolated osteoblasts, and osteoblastic cell lines. Calcified Tissue International., 54: 284-289
5.N Horikawa, K Kataha, N Watanabe, K Ishii, N Yanaihara, Y Tanaka, K Shigenobu, K Nakayama (1998). Biological & pharmaceutical bulletin 21: 1290-3.
6.T Grunditz, P Persson, R Hakanson, A Abosood, G Bottcher, C Rerup and Sundler (1989). Proc. NatI. Acad. Sci., 86: 1357-1361.
Heat Shock Protein Inhibitors
Definition
Benzoquinone Ansamycin
Geldanamycin are naturally occurring benzoquinone ansamycin antibiotics that can be isolated through fermentation of Streptomyces hygroscopicus. In addition, analogue compounds, such as the geldanamycin derivative 17 allylamino-17-demethoxygeldanamycin (17-AAG), have been shown to possess antitumor activity in several human xenograft models, including colon, breast, and prostate cancer and have been used in patient clinical trials. These compounds bind to the ATP/ADP binding pocket in the NH2-terminal domain with high affinity, inhibiting Hsp90, and thus are potent inhibitors of cancer cell growth and the malignant phenotype in a number of cancer cell types1.
Radicicol
Novobiocin, Coumermycin A1, and Clorobiocin
Mode of action
Functions
Reference:
1.Schulte TW, Neckers LM (1998). The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer. Chemother. Pharmacol, 42, 273-9.
2.Soga S, Neckers LM, Schulte TW, Shiotsu Y, Akasaka K, Narumi H, Agatsuma T, Ikuina Y, Murakata C, Tamaoki T, Akinaga S (1999). KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. Cancer Res., 59(12), 2931-8.
3.Moulin E, Barluenga S, Winssinger N (2005). Concise synthesis of pochnin A, an HSP90 inhibitor. Org. Lett., 8, 7(25), 5637-9.
4.Burlison JA, Neckers L, Smith AB, Maxwell A, Blagg BS (2006). Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90. J. Am. Chem. Soc., 128 (48), 15529-36.
5.David B. Solit, Andrea D. Basso, Adam B. Olshen, Howard I. Scher and Neal Rosen (2003). Inhibition of Heat Shock Protein 90 Function Down-Regulates Akt Kinase and Sensitizes Tumors to Taxol. Cancer Research 63, 2139-2144.
6.Antonov A, Snead C, Gorshkov B, Antonova GN, Verin AD and Catravas JD (2008). Heat Shock Protein 90 Inhibitors Protect and Restore Pulmonary Endothelial Barrier Function. Am. J. Respir. Cell Mol. Biol., 39 (5), 551-559.
Heat shock protein inhibitors bind to the ATP pocket in the N-terminal domain of the heat shock protein (HSP90) molecular chaperone. Inhibition of the ATPase activity results in the depletion of HSP90 client proteins, particularly kinases that are involved in signal transduction.
Benzoquinone Ansamycin
Geldanamycin are naturally occurring benzoquinone ansamycin antibiotics that can be isolated through fermentation of Streptomyces hygroscopicus. In addition, analogue compounds, such as the geldanamycin derivative 17 allylamino-17-demethoxygeldanamycin (17-AAG), have been shown to possess antitumor activity in several human xenograft models, including colon, breast, and prostate cancer and have been used in patient clinical trials. These compounds bind to the ATP/ADP binding pocket in the NH2-terminal domain with high affinity, inhibiting Hsp90, and thus are potent inhibitors of cancer cell growth and the malignant phenotype in a number of cancer cell types1.
Radicicol
Radicicol (RDC), isolated from Diheterospora chlamydosporia, has proven to have many downstream oncogenic effects through Hsp90 inhibition. A novel radicicol oxime derivative, radicicol 6-oxime (KF25706), has been shown to be potent antiproliferative activities against various human tumor cell lines in vitro and inhibited v-src- and K-ras-activated signaling as well as radicicol. KF25706 was also shown to compete with geldanamycin for binding to Hsp90. KF25706 was also shown to possess antitumor activity against human breast carcinoma MCF-7, colon carcinoma DLD-1, and vulval carcinoma A431 cell lines in vivo in an animal model2.
Isolation of the structurally similar pochonin family of natural products from Pochonia chlamydosporia has also shown promise in Hsp90 inhibition, particularly with pochonin A and pochonin D. Pochonin A and D have been shown to directly inhibit Hsp90. Pochonins A–F, while themselves displaying cytotoxicity in the micromolar range3.
Novobiocin, Coumermycin A1, and Clorobiocin
The coumermycin family of antibiotics, isolated from Streptomyces spheroids, has long been used clinically for antimicrobial purposes. Novobiocin in particular has been shown to display anti-cancer properties, and has been used in the clinic for many years. Ground breaking work by Neckers and co-workers demonstrated that this activity could be ascribed to novobiocin's Hsp90 inhibitory activity4.
Mode of action
Benzoquinone ansamycins, such as geldanamycin exhibit anticancer activity by binding to heat shock protein 90 (Hsp90), a molecular chaperone. In this interaction, geldanamycin competes with adenosine triphosphate at the N-terminal-binding site of Hsp90. The interaction results in the proteosome-mediated degradation of several important oncogenic proteins, including Raf-1, c-ErbB2, and mutant (but not wild-type) p53 (also known as TP53). Clearly, this molecular profile offers considerable potential for antitumor activity. Further investigation proved that GDA specifically inhibited the Src-Hsp90 heteroprotein complex, facilitating degradation of the client protein and thus attributing to its antitumor properties1.
To date, radicicol (RDC) is the most potent natural product inhibitor of Hsp90,. Its mechanism of action is similar to that of GDA, in that it binds to the N-terminal ATP-binding pocket of Hsp90.
Mechanistically, they bind the ATP binding pocket of DNA gyrase, another member of the GHKL superfamily, thus preventing ATP hydrolysis2.
Functions
Inhibition of Heat Shock Protein 90 Function Down-Regulates Akt Kinase - The phosphatidylinositol 3'-kinase/Akt pathway is activated frequently in human cancer, and has been implicated in tumor proliferation, cell survival, and resistance to apoptotic stimuli. Akt forms a complex with heat shock protein (Hsp) 90 and Cdc37, and inhibitors of Hsp90 cause Akt degradation. 17-AAG inhibits Akt activation and expression in tumors, and has antitumor activity in breast cancer xenografts. The combination of 17-AAG and Taxol is synergistic, and 17-AAG sensitizes tumor cells to Taxol-induced apoptosis in a schedule-dependent manner. Enhancement was schedule-dependent and maximal when Taxol and 17-AAG were administered on the same day. These results suggest that Hsp90 inhibitors can effectively suppress Akt activity in animal models of human cancer at nontoxic doses, thus sensitizing tumor cells to proapoptotic stimuli5.
Heat Shock Protein 90 Inhibitors Protect and Restore Pulmonary Endothelial Barrier Function - Exposure of confluent bovine pulmonary arterial endothelial cell (BPAEC) monolayer to TGF 1, thrombin, bacterial LPS or VEGF, increased BPAEC permeability, as revealed by decreased transendothelial electrical resistance (TER). Treatment of injured endothelium with hsp90 inhibitors completely restored TER of BPAEC. Similarly, pre-incubation of BPAEC with hsp90 inhibitors prevented the decline in TER induced by the exposure to thrombin, LPS, VEGF or TGFb1. Additionally, hsp90 inhibitors restored the EC barrier function after nocodazole- induced hyperpermeability. These effects of the hsp90 inhibitors were associated with the restoration of TGFb1- or nocodazole- induced decrease in VE-cadherin and b-catenin expression at EC junctions. The protective effect of hsp90 inhibitors on TGFb1-induced hyper-permeability was critically dependent upon preservation of F-actin cytoskeleton and was associated with the inhibition of agonist-induced myosin light chain (MLC) and myosin phosphatase target subunit 1 (MYPT1) phosphorylation, F-actin stress fibers formation, microtubule disassembly, increase in hsp27 phosphorylation, and association of hsp90 with hsp27. This implies that hsp90 inhibitors exert barrier protective effects on BPAEC, via inhibition of hsp27-mediated, agonist-induced cytoskeletal-rearrangement.
Reference:
1.Schulte TW, Neckers LM (1998). The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer. Chemother. Pharmacol, 42, 273-9.
2.Soga S, Neckers LM, Schulte TW, Shiotsu Y, Akasaka K, Narumi H, Agatsuma T, Ikuina Y, Murakata C, Tamaoki T, Akinaga S (1999). KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. Cancer Res., 59(12), 2931-8.
3.Moulin E, Barluenga S, Winssinger N (2005). Concise synthesis of pochnin A, an HSP90 inhibitor. Org. Lett., 8, 7(25), 5637-9.
4.Burlison JA, Neckers L, Smith AB, Maxwell A, Blagg BS (2006). Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90. J. Am. Chem. Soc., 128 (48), 15529-36.
5.David B. Solit, Andrea D. Basso, Adam B. Olshen, Howard I. Scher and Neal Rosen (2003). Inhibition of Heat Shock Protein 90 Function Down-Regulates Akt Kinase and Sensitizes Tumors to Taxol. Cancer Research 63, 2139-2144.
6.Antonov A, Snead C, Gorshkov B, Antonova GN, Verin AD and Catravas JD (2008). Heat Shock Protein 90 Inhibitors Protect and Restore Pulmonary Endothelial Barrier Function. Am. J. Respir. Cell Mol. Biol., 39 (5), 551-559.
GSK-3ß (Glycogen Synthase Kinase - 3ß)
Definition
Glycogen synthase kinase 3 (GSK3 ) is a serine/threonine kinase that has enzymatic activity regulated by many signaling pathways and by distinct multiprotein complexes.
Related peptides
GSK3 belongs to the superfamily of mitogen-activated protein (MAP) kinases. Mammalian cells have two glycogen synthase kinase isoforms: and . The protein sequences deviate substantially outside the kinase core (308 residues), which have 97% sequence similarity.
Discovery
GSK-3 was first identified as one of the protein kinases that phosphorylates glycogen synthase, the rate-limiting enzyme of glycogen deposition1,2.. In 1990, Woodgett JR and others, identified the cDNA sequence encoding the 47Kda protein, GSK 3b and co-purified GSK-3a and b, from bovine brain3.
Structural Characteristics
GSK3 has the typical two-domain kinase fold with a -strand domain (residues 25-138) at the N-terminal end and an -helical domain at the C-terminal end (residues 139-343). The ATP-binding site is at the interface of the -helical and -strand domain and is bordered by the glycine-rich loop and the hinge. The activation loop (residues 200-226) runs along the surface of the substrate binding groove. The C-terminal 39 residues (residues 344-382) are outside the core kinase fold and form a small domain that packs against the -helical domain. The -strand domain consists of seven antiparallel -strands: strands 2-6 form a -barrel that is interrupted between strand 4 and 5 by a short helix (residue 96-102) that packs against the -barrel. This helix is conserved in all kinases, and two of its residues play key roles in the catalytic activity of the enzyme. Arg 96 is involved in the alignment of the two domains. Glu 97 is positioned in the active site and forms a salt bridge with Lys 85, a key residue in catalysis. GSK3 has two phosphorylation sites that influence the catalytic activity of the protein. Ser 9 is the phosphorylation site for AKT, and the phosphorylation of this residue inactivates GSK3 . Phosphorylation of Tyr 216, located on the activation loop, increases the catalytic activity.
Mode of action
GSK3 phosphorylates multiple substrates but does not phosphorylate all targets in the same manner and with the same efficiency. The canonical phosphorylation sequence recognized by GSK3 , SXXXS, contains two Ser residues separated by three residues. Multiple copies of this motif can be present in the substrate. Several protein substrates, such as glycogen synthase, eukaryotic initiation factor 2B (eIF2b) and adenomatous polyposis coli protein (APC), are first phosphorylated by a different kinase at the P + 4 serine in the SXXXS motif before GSK3 phosphorylates the serine in the P position. This is called primed phosphorylation and is 100-1000 more efficient than phosphorylation without priming. Glycogen synthase has multiple serines (residues 640, 644, 648 and 652) separated by three residues, and those Ser residues are phosphorylated sequentially by GSK3 from the C-terminal end after Ser 656 has been phosphorylated by casein kinase II. GSK3 uses the phosphorylated serine or threonine at the P + 4 position of the substrate to align of the two domains for optimal catalytic activity4.
Functions
Originally identified for its role in the regulation of glycogen metabolism, it is now known that GSK-3ß plays a key role in cellular processes as diverse as cytoskeletal regulation, cell cycle progression, apoptosis, cell fate and specification, and transcriptional/translational initiation. Therefore, functional kinase activity of GSK-3ß is important in a variety of biological and biochemical processes and altered GSK-3ß activity can contribute to a number of pathological processes including bipolar mood disorder, schizophrenia, heart disease, neurodegeneration, Alzheimer's disease and diabetes mellitus5.
References
1.Embi N, Rylatt DB and Cohen P (1980). Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur. J. Biochem., 107, 519–527.
2.Hemmings BA, Yellowless D, Kernohan JC, Cohen P (1982). Purification of Glycogen Synthase Kinase 3 from Rabbit Skeletal Muscle, Eur. J. Biochem., 119, 445-451.
3.Woodgett JR (1990). Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J., 9(8), 2431-8.
4.Haar E, Coll JT, Austen DA, Hsiao HM, Swenson L and Jain J (2001). Structure of GSK3b reveals a primed phosphorylation mechanism. Nature Structural Biology, 8, 593 – 596.
5.Bowley E, Mulvihill E, Howard JC, Pak BJ, Gan BS and O'Gorman DB (2005). A novel mass spectrometry-based assay for GSK-3ß activity. BMC Biochemistry, 6, 29.
Glycogen synthase kinase 3 (GSK3 ) is a serine/threonine kinase that has enzymatic activity regulated by many signaling pathways and by distinct multiprotein complexes.
Related peptides
GSK3 belongs to the superfamily of mitogen-activated protein (MAP) kinases. Mammalian cells have two glycogen synthase kinase isoforms: and . The protein sequences deviate substantially outside the kinase core (308 residues), which have 97% sequence similarity.
Discovery
GSK-3 was first identified as one of the protein kinases that phosphorylates glycogen synthase, the rate-limiting enzyme of glycogen deposition1,2.. In 1990, Woodgett JR and others, identified the cDNA sequence encoding the 47Kda protein, GSK 3b and co-purified GSK-3a and b, from bovine brain3.
Structural Characteristics
GSK3 has the typical two-domain kinase fold with a -strand domain (residues 25-138) at the N-terminal end and an -helical domain at the C-terminal end (residues 139-343). The ATP-binding site is at the interface of the -helical and -strand domain and is bordered by the glycine-rich loop and the hinge. The activation loop (residues 200-226) runs along the surface of the substrate binding groove. The C-terminal 39 residues (residues 344-382) are outside the core kinase fold and form a small domain that packs against the -helical domain. The -strand domain consists of seven antiparallel -strands: strands 2-6 form a -barrel that is interrupted between strand 4 and 5 by a short helix (residue 96-102) that packs against the -barrel. This helix is conserved in all kinases, and two of its residues play key roles in the catalytic activity of the enzyme. Arg 96 is involved in the alignment of the two domains. Glu 97 is positioned in the active site and forms a salt bridge with Lys 85, a key residue in catalysis. GSK3 has two phosphorylation sites that influence the catalytic activity of the protein. Ser 9 is the phosphorylation site for AKT, and the phosphorylation of this residue inactivates GSK3 . Phosphorylation of Tyr 216, located on the activation loop, increases the catalytic activity.
Mode of action
GSK3 phosphorylates multiple substrates but does not phosphorylate all targets in the same manner and with the same efficiency. The canonical phosphorylation sequence recognized by GSK3 , SXXXS, contains two Ser residues separated by three residues. Multiple copies of this motif can be present in the substrate. Several protein substrates, such as glycogen synthase, eukaryotic initiation factor 2B (eIF2b) and adenomatous polyposis coli protein (APC), are first phosphorylated by a different kinase at the P + 4 serine in the SXXXS motif before GSK3 phosphorylates the serine in the P position. This is called primed phosphorylation and is 100-1000 more efficient than phosphorylation without priming. Glycogen synthase has multiple serines (residues 640, 644, 648 and 652) separated by three residues, and those Ser residues are phosphorylated sequentially by GSK3 from the C-terminal end after Ser 656 has been phosphorylated by casein kinase II. GSK3 uses the phosphorylated serine or threonine at the P + 4 position of the substrate to align of the two domains for optimal catalytic activity4.
Functions
Originally identified for its role in the regulation of glycogen metabolism, it is now known that GSK-3ß plays a key role in cellular processes as diverse as cytoskeletal regulation, cell cycle progression, apoptosis, cell fate and specification, and transcriptional/translational initiation. Therefore, functional kinase activity of GSK-3ß is important in a variety of biological and biochemical processes and altered GSK-3ß activity can contribute to a number of pathological processes including bipolar mood disorder, schizophrenia, heart disease, neurodegeneration, Alzheimer's disease and diabetes mellitus5.
References
1.Embi N, Rylatt DB and Cohen P (1980). Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur. J. Biochem., 107, 519–527.
2.Hemmings BA, Yellowless D, Kernohan JC, Cohen P (1982). Purification of Glycogen Synthase Kinase 3 from Rabbit Skeletal Muscle, Eur. J. Biochem., 119, 445-451.
3.Woodgett JR (1990). Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J., 9(8), 2431-8.
4.Haar E, Coll JT, Austen DA, Hsiao HM, Swenson L and Jain J (2001). Structure of GSK3b reveals a primed phosphorylation mechanism. Nature Structural Biology, 8, 593 – 596.
5.Bowley E, Mulvihill E, Howard JC, Pak BJ, Gan BS and O'Gorman DB (2005). A novel mass spectrometry-based assay for GSK-3ß activity. BMC Biochemistry, 6, 29.
Subscribe to:
Posts (Atom)